April 2026
Longevity research from April 2026, curated and analyzed through the EDGE Framework.
Some Researchers Choose Replacement Over Repair in Aging
Replacement-based interventions—substituting damaged cells, tissues, organs, and physiological systems with biological or synthetic alternatives—are emerging as a pragmatic complement to endogenous repair strategies in aging research. Multiple research organizations are advancing clinical applications ranging from stem cell therapies for structural injuries to bioprinted organs and genetic replacements derived from long-lived species.
RETRACTION: Antileukotriene Therapy by Reducing Tau Phosphorylation Improves Synaptic Integrity and Cognition of P301S Transgenic Mice
This retraction notice withdraws a 2018 study on antileukotriene therapy and tau phosphorylation in a mouse model of neurodegeneration due to image manipulation and duplication across multiple figures. The unreliability of the underlying data means the claimed cognitive and synaptic benefits cannot be considered evidence-based.
Rafael Holdings gains exclusive MIT Alzheimer’s patent
Rafael Holdings secured exclusive MIT patent rights for cyclodextrin-based molecules targeting ApoE4-positive Alzheimer's disease by restoring cholesterol transport between brain cells. This represents a shift from amyloid-clearance paradigms toward addressing the cellular infrastructure that prevents pathological buildup in the first place.
Antag’s obesity drug targets fat storage, not appetite
AT7687, a GIP receptor antagonist, targets fat storage pathways rather than appetite suppression, demonstrating tolerability and early metabolic improvements in human trials. Combined with cagrilintide in preclinical studies, the compound achieved weight loss exceeding either drug alone while preserving lean mass and improving insulin sensitivity without increased gastrointestinal burden.
A one-shot cure for diabetes? Sana Biotechnology makes its move
Sana Biotechnology and Mayo Clinic are advancing SC451, a cell therapy that replaces destroyed pancreatic islet cells in Type 1 diabetes by engineering them to evade immune attack, potentially eliminating the need for lifelong insulin management. Early data shows transplanted cells remaining functional for over a year without immunosuppression, establishing a proof-of-concept for broader tissue replacement applications.
Metashape Pharma to present new data on GLP-1 combination, muscle health
Metashape Pharma's preclinical data demonstrate that MS 001, a purine nucleoside phosphorylase inhibitor, combined with semaglutide produces selective fat loss while preserving muscle mass in diet-induced obese mice through increased thermogenesis. This addresses a critical limitation of GLP-1 monotherapy—undesired muscle loss during weight reduction—with direct implications for preserving metabolic capacity and physical function during longevity-focused weight management.
VectorY Therapeutics clears UK and EU to start VTx-002 ALS trial
VectorY Therapeutics has gained regulatory approval from UK and EU authorities to expand its Phase 1/2 trial of VTx-002, a first-in-class vectorized antibody targeting pathological TDP-43 aggregates in amyotrophic lateral sclerosis. The trial will enroll 12 adults across multiple sites to evaluate safety, tolerability, and exploratory efficacy, with TDP-43 present in up to 97% of ALS patients.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health, combining epigenetic testing platforms, laboratory infrastructure, and personalized intervention products. The merger positions epigenetic age assessment as a diagnostic tool paired with targeted supplementation and lifestyle recommendations for consumers pursuing longevity optimization.
Inside the race to build longevity-ready business models
Business models built on traditional three-stage life assumptions are becoming obsolete as longevity reshapes market demand across leisure, housing, beauty, and healthcare sectors. Organizations that embed healthspan optimization and address demographic health disparities position themselves to capture significant commercial opportunity while improving population health outcomes.
NorthStrive files U.S. patent application for EL-22 formulations
NorthStrive Biosciences filed a patent application for EL-22, a myostatin-engineered probiotic designed to preserve muscle mass across multiple conditions including GLP-1 receptor agonist-induced muscle loss, sarcopenia, and disuse atrophy. The filing protects formulations and dosing regimens, positioning the compound as a therapeutic intervention for muscle-wasting states with significant implications for metabolic health and longevity.
Aesthetic Record acquires Joya Health to expand skin health network
Aesthetic Record acquired Joya Health to integrate employer-based skin health benefits with a nationwide provider network, creating a unified platform for dermatological and aesthetic care access. This consolidation addresses fragmentation in patient acquisition and provider matching within the aesthetic medicine sector.
Environmental Enrofloxacin Exposure as a Modifiable Driver of Mitochondria‐Mediated Intestinal Aging and Barrier Dysfunction
Chronic low-dose enrofloxacin exposure accelerates intestinal aging through mitochondrial dysfunction and barrier compromise, with mitochondrial-targeted antioxidant treatment reversing these effects. Environmental antibiotic contamination represents a modifiable driver of gut aging and chronic intestinal disease with direct impact on biological aging markers in humans.
Plasma Dilution After Myocardial Ischemia–Reperfusion Injury Promotes Cardiac Repair, Heart Performance, and Recovery of Motor Function and Endurance in Old Mice
Plasma dilution performed 24 hours after myocardial ischemia–reperfusion injury in aged mice significantly improved cardiac function, reduced fibrosis and inflammation, and restored physical performance through enhanced cellular repair and modified inflammatory signaling pathways. This finding addresses a critical gap in aging-relevant cardiac research by demonstrating that manipulating the blood's humoral environment after acute injury can shift the trajectory of tissue recovery in older organisms.
Nuchido announced as Catalyst Partner for The Longevity Show
Nuchido addresses NAD+ decline through targeted restoration of the salvage pathway rather than simple precursor replacement, supported by randomized controlled human trials demonstrating improvements in inflammation, glycation, and biological age markers. This systems-biology approach represents a maturation of the NAD+ intervention landscape toward mechanistic rather than marketing-driven solutions.
Daytime Napping and Mortality Association in Older Adults
Excessive daytime napping—particularly longer duration and morning timing—associates with increased mortality risk in older adults, with effects comparable to accelerated aging. The relationship appears driven by underlying systemic dysfunction rather than sleep disorder alone, making napping patterns a measurable indicator of health status.
Super Age debuts world’s first longevity fitness games
The Super Age Games reframe competitive fitness around healthspan—the quality and sustainability of functional life—rather than isolated performance metrics. This shifts how populations measure aging success, integrating physical, cognitive, metabolic, and social dimensions into a single assessment model that reflects real-world health integration.
RETRACTION: The 12‐15‐Lipoxygenase is a Modulator of Alzheimer's‐Related Tau Pathology In Vivo
A 2013 study claiming 12-15-lipoxygenase modulates Alzheimer's-related tau pathology has been retracted due to image duplication in key figures. The retraction undermines the study's conclusions about this enzyme's role in neurodegeneration.
The AI race to stop chronic disease just got funded with $3.5m
Dehaze, a Munich-based startup, has secured $3.5 million in funding to develop AI that processes the 97% of patient data currently unused in clinical decision-making, aiming to detect chronic disease earlier when intervention is more effective and less costly. Early detection of chronic conditions—currently missed in roughly one-third of cases until advanced stages—represents one of the largest opportunities for reducing healthcare spending and mortality.
Replacement‐Based Ageing Interventions for Systemic Rejuvenation: Shaping Longevity Science and Clinical Directions
Replacement-based interventions—which remove or export molecular, organellar, and cellular damage—offer a mechanistic approach to systemic rejuvenation that could extend healthy lifespan beyond conventional therapeutics. This framework integrates bioengineering strategies with regenerative approaches to address multiple forms of age-related damage simultaneously across tissues and regulatory networks.
Infinite Epigenetics acquires Tally Health
Infinite Epigenetics acquired Tally Health to integrate epigenetic testing with clinical infrastructure and consumer interventions, creating a closed-loop system that aims to move biological age measurement from research curiosity into actionable preventive healthcare. The consolidation represents an attempt to resolve the gap between epigenetic data capture and demonstrable clinical outcomes.
Alterity Therapeutics receives positive regulatory feedback on ATH434
Alterity Therapeutics received FDA alignment on manufacturing and chemistry for ATH434, a therapeutic candidate for multiple system atrophy that demonstrated clinically meaningful efficacy in Phase 2 trials. The regulatory feedback positions the company to initiate pivotal Phase 3 development while scaling manufacturing capacity.
Aspen’s autologous cell therapy shows promising Phase 1/2a results
Aspen's autologous iPSC-derived dopaminergic cell therapy demonstrated clinically meaningful improvements in motor function and quality of life in early Parkinson's disease patients, with durable cell engraftment and acceptable safety profile at 12 months. This represents a regenerative medicine approach that bypasses the need for immunosuppression by using a patient's own reprogrammed cells.
Voyager IV gene therapies for Alzheimer’s disease highlighted at ASGCT 2026
Voyager Therapeutics will present VY1706, an intravenously delivered gene therapy targeting tau pathology in Alzheimer's disease, at ASGCT 2026. Preliminary three-month toxicology data in non-human primates demonstrate pharmacological efficacy and safety, with first-in-human dosing anticipated in late 2026.
Annovis publishes Phase 2/3 buntanetap findings in Nature journal
Buntanetap, an oral small molecule, demonstrated dose-dependent cognitive improvements and reduced neurotoxic protein markers in patients with mild to moderate Alzheimer's disease over 12 weeks. The findings suggest potential disease-modifying activity through reduction of tau pathology and neuroinflammation, advancing a mechanism distinct from current monoclonal antibody approaches.
T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets
Aging T cells develop senescence characteristics that drive chronic inflammatory skin diseases through dysregulated signaling pathways and secretion of pro-inflammatory factors. Targeting senescent T cells or their signaling cascades offers a mechanism-based approach to achieving sustained remission in conditions like psoriasis and atopic dermatitis.
Multimodal data analysis reveals asynchronous aging dynamics across female reproductive organs
Deep learning analysis of histological and transcriptomic data from over 300 female donors reveals that reproductive organs age asynchronously rather than in lockstep, with menopause functioning as a critical inflection point detectable in circulating protein signatures. This challenges the assumption of synchronized aging across organ systems and identifies tissue-specific vulnerability windows relevant to longevity and disease prevention.
A Popular Senolytic Treatment Causes Brain Damage in Mice
Dasatinib and quercetin (D+Q), a widely used senolytic combination, impairs oligodendrocyte function and reduces myelination in the brain through endoplasmic reticulum stress, causing morphological changes similar to those seen in multiple sclerosis. This finding indicates that senolytic interventions carry neurological risks that warrant careful evaluation before clinical deployment.
Endlyz raises Seed 2 financing, leans into root-cause neuroscience
Endlyz Therapeutics is pursuing disease modification in Parkinson's by targeting lysosomal dysfunction at the cellular level, addressing the root cause of neurodegeneration rather than managing symptoms. This approach represents a shift toward interventions that could slow disease progression before irreversible damage accumulates.
Genflow teams with Acuitas on gene delivery in fully-funded deal
Genflow Biosciences and Acuitas Therapeutics have partnered to optimize delivery of a SIRT6 gene therapy targeting aging-related processes. The collaboration underscores that therapeutic efficacy depends equally on how genetic material reaches target tissues as on the genetic intervention itself.
Obesity’s Effects on the Immune System May Linger for Years
T cells retain pro-inflammatory characteristics long after weight loss, perpetuating immune dysregulation in previously obese individuals. This 'obesity memory' may persist for years in humans despite normalization of body mass, suggesting that metabolic recovery and immune recovery operate on different timelines.
Virus-inspired shot targets preventive longevity
Smart Nanovirus has launched RIGVIR X, a monthly liquid supplement designed to support immune surveillance and detect abnormal cellular activity before disease progression. The product represents a shift toward preventive intervention decades before clinical disease would typically manifest, using virus-inspired mechanisms rather than conventional pharmaceuticals.
Knee implant outperforms standard care at 5 years
A scaffold-based cartilage repair implant demonstrated superior outcomes to standard surgical approaches over five years, including reduced pain and improved mobility across patients with and without early osteoarthritis. This addresses a treatment gap for patients with moderate joint damage who are ineligible for full replacement but fail to benefit durably from conventional repair.
Non-Pharmacological Sleep Interventions for Dementia Caregivers; A Systematic Review of Randomized Controlled Trials
Dementia caregivers experience chronic sleep disruption that impairs their own health and caregiving capacity. Non-pharmacological interventions—behavioral modifications, cognitive techniques, and environmental adjustments—demonstrate measurable improvements in sleep quality and duration when implemented consistently, with secondary benefits to emotional regulation and stress resilience.
Coultreon raises $125m for immune resilience
Coultreon Biopharma raised $125 million to advance COL-5671, an oral SIK3 inhibitor designed to restore immune balance rather than blunt inflammatory suppression in autoimmune disease. The approach targets a mechanism relevant to chronic immune dysregulation associated with aging, positioning the therapy as a potential bridge between disease treatment and healthspan optimization.
Reducing cardiovascular risk: a playbook for lipid-lowering pharmacotherapy
A systematic approach to lipid-lowering pharmacotherapy uses risk stratification and a six-step protocol to guide drug selection and escalation, optimizing cardiovascular protection across heterogeneous patient populations. This framework addresses the gap between guideline recommendations and individualized clinical decision-making in managing atherosclerotic cardiovascular disease risk.
FDA clears Denali biologic as first brain-penetrating therapy
The FDA approved Avlayah, an enzyme replacement therapy that crosses the blood-brain barrier to treat neurologic manifestations of Hunter syndrome in children. The therapy achieved 91% reduction in cerebrospinal fluid heparan sulfate accumulation, addressing a progressive lysosomal storage disorder that damages neural tissue.
Alnylam advances diabetes candidate ALN-4324 into Phase 2
Alnylam has advanced ALN-4324, an RNAi therapeutic targeting GRB14, into Phase 2 trials for Type 2 diabetes. The candidate is designed to improve whole-body insulin sensitivity through a single subcutaneous injection, representing a potential therapeutic approach to a primary metabolic dysfunction underlying age-related disease progression.
Preclinical in vivo CAR T data from Sana at ASGCT meeting in Boston
Sana Biotechnology presented preclinical nonhuman primate data for SG293, a fusogen-based delivery system designed to generate CAR-T cells in vivo with CD8-targeted specificity while sparing hepatic tissue. This approach addresses a critical challenge in cell therapy: achieving therapeutic effect without systemic toxicity.
The Impact of Hurricane Maria on Puerto Rico’s Long-Term Care Settings
Hurricane Maria exposed critical vulnerabilities in Puerto Rico's long-term care infrastructure, with aging populations facing extended periods without adequate medical support, power, and resource access. This research documents how environmental disruption compounds existing healthcare deficits and accelerates functional decline in vulnerable populations.
Muscle as medicine: Is strength the missing link in longevity?
Muscle strength, not weight loss, emerges as a primary determinant of longevity and systemic resilience. Grip strength serves as a measurable proxy for whole-body physiological capacity and mortality risk, challenging decades of weight-focused health messaging.
HR leaders urged to act on longevity now
Employers are transitioning from reactive wellness programs to data-driven preventive health strategies as workforces age and the gap between lifespan and healthspan widens. This shift positions HR leaders as active participants in longevity science implementation, though adoption remains uneven and raises substantive questions about data governance, employee trust, and ethical boundaries.
FDA greenlights faster path for knee osteoarthritis drug
4Moving Biotech's experimental drug 4P004 has received FDA Fast Track designation for knee osteoarthritis, signaling regulatory recognition of both the scale of patient suffering and the drug's potential to modify disease progression rather than manage symptoms alone. The designation accelerates development timelines and could reshape treatment of a condition affecting 374 million people globally.
A shorter path into personalized longevity care
Innovative Vitality launched Longevity Labs & Provider Review, a lower-commitment program that combines comprehensive biomarker analysis (50+ markers), body composition assessment, and a one-hour clinician consultation to identify health gaps between normal lab results and how patients actually feel. The program delivers a personalized health roadmap without requiring ongoing enrollment, addressing the clinical limitation that normal test results often mask suboptimal function.
A Robust Senescence Response Helps Wounds Heal
Younger mice demonstrate faster wound healing due to a more robust senescent cell response, while the accumulation of senescent cells with age paradoxically impairs regeneration. This reveals a temporal window in which senescent cell activation supports tissue repair before becoming detrimental.
Associations of Instrumental Activities of Daily Living, Self-Reported Falls, and Depression With Subjective Cognitive Decline Among Older Adults
Subjective cognitive decline in older adults correlates with reduced capacity for instrumental daily activities, prior falls, and depressive symptoms. This association suggests that perceived cognitive changes may reflect broader functional and neurological stress rather than isolated memory loss.
Pain and Social Isolation as Mediators of the Longitudinal Association Between Sleep Problems and Frailty in U.S. Older Adults
Sleep disruption in older adults increases frailty risk through two distinct pathways: chronic pain and social isolation. This longitudinal finding identifies modifiable mechanisms that connect nighttime physiology to the decline of physical resilience in aging.
Short‐Term Dietary Intervention Alters Physiological Profiles Relevant to Ageing
A 4-week dietary intervention in adults aged 65–75 reduced KDM-derived biological age estimates, with the greatest effects seen in high-carbohydrate and semi-vegetarian groups. This rapid shift in composite biomarkers suggests diet produces measurable physiological changes relevant to aging trajectories, though longer-term data are needed to establish impact on disease risk.
Calluna completes enrollment in Phase 2 AURORA study
Calluna Pharma has completed enrollment in a Phase 2 trial of CAL101, a monoclonal antibody targeting S100A4 to preserve lung function in idiopathic pulmonary fibrosis, a disease with median survival of 3-5 years. Topline results are expected in Q1 2027.
Insilico Medicine nominates UAE’s first preclinical candidate
Insilico Medicine nominated ISM0387, a PRMT5 inhibitor discovered through AI-driven drug design, as the UAE's first preclinical candidate. The molecule demonstrates improved selectivity, brain penetration, and efficacy in disease models, discovered in six months using generative AI and quantum computing approaches.
Nuritas brings PeptiStrong clinical momentum to Vitafoods
Nuritas is conducting a 30-day randomized controlled trial comparing PeptiStrong (a fava bean-derived peptide) plus whey protein against whey protein alone in adults aged 60–85, with grip strength as the primary outcome and secondary measures including gait speed, balance, and inflammatory markers. The trial addresses a direct mechanism relevant to aging: preserving muscle function and mass in older populations.
#389 – Thinking scientifically: why it’s hard, why it matters, and a practical toolkit
Scientific thinking is a method for reducing error over time rather than achieving absolute certainty. This epistemological approach directly supports longevity optimization by establishing how to evaluate competing health claims and adjust protocols based on evidence rather than intuition or ideology.
D-pinitol extends the lifespan of Caenorhabditis elegans through integrated antioxidant defense, proteostasis, and autophagy signaling
D-pinitol, a naturally occurring inositol derivative, extends lifespan in C. elegans by coordinating three distinct cellular mechanisms: antioxidant defense, protein stability (proteostasis), and autophagy. This multi-pathway activation suggests a compound that addresses fundamental aging processes rather than targeting a single intervention point.
There is no safe gamble with high LDL cholesterol
High LDL cholesterol carries cardiovascular risk regardless of body composition or metabolic phenotype. The concept of "lean mass hyper-responders"—individuals who gain muscle while maintaining low body fat despite elevated LDL—does not eliminate the atherogenic potential of circulating lipoproteins.
Diminished and Altered Cellular Senescence Response in Delayed Wound Healing of Aging
Wound healing in young skin relies on a coordinated senescence response in fibroblasts that produces tissue-remodeling proteins and supports closure. In aged individuals, this response is both diminished and functionally altered toward inflammation, directly impairing repair capacity and contributing to delayed healing.
Histone Deacetylase 9 Gene Deletion Ameliorates Aging‐Related Adipose Tissue Senescence and Mitochondrial Dysfunction in Mice
HDAC9 gene deletion in mice reduces age-related fat tissue senescence and restores mitochondrial function through upregulation of thiosulfate sulfurtransferase (TST), a protein whose decline contributes to metabolic dysfunction during aging. This identifies HDAC9 as a druggable epigenetic target for preserving adipose tissue health.
Inferring Gene Regulatory Network Architecture Underlying Complex Traits: An Integrative Analysis of Mutant Lifespan and Gene Expression Profiles Identifies Master Regulators and Key Functional Modules for Yeast Aging
Researchers identified a hierarchical gene regulatory network controlling yeast lifespan, where peripheral genes act through master regulators that converge on functional modules governing stress response, autophagy, and proteostasis. This architecture provides a framework for dissecting genetic complexity in aging and maps directly to mechanisms that influence human longevity pathways.
Aging‐Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment
In aged ovarian cancer, elevated succinate in the tumor microenvironment drives metabolic reprogramming of regulatory T cells, amplifying immunosuppression and reducing survival. Pharmacological inhibition of succinate metabolism restores effector T cell activity and improves outcomes, identifying a metabolic mechanism underlying age-related cancer progression.
The Myokine Irisin Represents an Indirect Pathway Linking Exercise to Hippocampal Subfields Relevant to Alzheimer's Disease and Neurogenesis
Exercise increases circulating irisin, a myokine that mediates preservation of hippocampal volume in older adults, with the strongest effects in CA1, CA3, and CA4 subfields—regions critical for memory formation and vulnerable to Alzheimer's pathology. This represents the first human evidence of the molecular mechanism by which physical activity protects hippocampal structure.
Long‐Term Stress Adaptation as a Highly‐Conserved Key Factor in Yeast Aging
Prolonged stress—distinct from acute stress—activates molecular pathways in yeast that recapitulate aging hallmarks including proteostasis collapse and epigenetic dysregulation. These changes are reversible upon stress relief, and the underlying genes are conserved across all life domains, suggesting aging may represent a maladaptive long-term stress response rather than passive damage accumulation.
Decellularized Aged Bruch's Membrane Confers Unique Biochemical Cues to Retinal Pigment Epithelium for In Vitro Modeling of Age‐Related Macular Degeneration
Researchers created an in vitro model of age-related macular degeneration using decellularized aged Bruch's membrane, which induced AMD-like phenotypes in retinal pigment epithelium including barrier dysfunction, drusen component expression, and complement activation. This biomaterial-based approach identifies specific biochemical cues that drive AMD pathology and provides a platform for understanding disease mechanisms at the tissue interface level.
Insilico forms industry’s first AI Longevity Board
Insilico Medicine has established an industry-focused Longevity Board to guide AI-driven drug development targeting aging itself rather than individual diseases. The board represents a shift from academic longevity research toward pharmaceutical scalability, with leadership from both the biotech sector and major pharmaceutical companies.
Longevity education finds its clinical footing
Structured longevity medical education is transitioning from fragmented knowledge to standardized clinical pathways, with the pairing of academic rigor (NUS Academy for Healthy Longevity) and practical implementation (Longevity Academy) signaling institutional maturation of the field. This development addresses the persistent gap between scientific discovery and clinical practice, establishing longevity medicine as a legitimate career pathway rather than a peripheral specialty.
Reprogrammed Cardiomyocytes Soften the Blow in Heart Attack
Partial reprogramming of heart muscle cells using three Yamanaka factors (OCT4, SOX2, KLF4) enables cardiomyocytes to complete cell division after myocardial infarction in mice by dismantling their contractile scaffold without triggering uncontrolled proliferation. This approach addresses a fundamental barrier to cardiac regeneration: mature heart cells lose divisibility because their rigid internal structure prevents cytokinesis, even when DNA replication is initiated.
Final patient out in AlzeCure’s study on Alzheimer’s
AlzeCure Pharma completed Phase Ib dosing of ACD856, demonstrating a wider-than-expected therapeutic window and safety profile across repeated higher doses. The completion positions the compound for Phase II trials and exploration across multiple neurological indications beyond Alzheimer's disease.
New FDA-cleared Cala device adapts to Parkinson’s tremor
The FDA-cleared Cala kIQ Plus device uses adaptive nerve stimulation to reduce hand tremors in Parkinson's disease and essential tremor by learning individual tremor patterns and adjusting therapy in real time. This approach prioritizes functional control and daily-life usability over complete tremor elimination, with emerging data suggesting higher responder rates and bilateral improvements in essential tremor.
Alterity presents new analysis of ATH434 Phase 2 data
ATH434, an oral iron chaperone, demonstrated disease-modifying effects in Phase 2 trials for Multiple System Atrophy, slowing disease progression by 35-53% relative to placebo across measured outcomes. These results position the compound for Phase 3 evaluation and suggest that reducing iron-driven neurodegeneration represents a viable intervention strategy in this progressive neurodegenerative disorder.
Rafael Holdings secures MIT patent license for cyclodextrins
Cyclo Therapeutics secured an exclusive MIT patent license for cyclodextrin use in ApoE4-positive Alzheimer's disease patients, a population representing 50-70% of Alzheimer's cases. The mechanism targets cholesterol transport in the central nervous system to address amyloid and tau pathology, with Phase 3 results expected in Q3 2026.
4Moving Biotech granted FDA fast track for 4P004
The FDA granted Fast Track Designation to 4P004, a GLP-1 analog designed for direct injection into the knee joint to treat osteoarthritis with inflammation in patients who have failed two prior drug therapies. The designation accelerates regulatory review for a candidate positioned as the first disease-modifying treatment targeting underlying joint degradation rather than symptoms alone.
Antag Therapeutics to present AT7687 data at ADA 2026
Antag Therapeutics is advancing AT7687, a GIP receptor antagonist peptide, showing tolerability and weight loss potential in early human trials and demonstrating synergistic metabolic benefits when combined with cagrilintide in preclinical work. The compound represents a mechanistic approach to obesity and insulin resistance through peptide-based receptor antagonism rather than agonism.
Springfield Wellness Center marks 25 years of NAD+ IV therapy
Springfield Wellness Center has operated for 25 years using intravenous NAD+ therapy as part of a multimodal protocol for addiction recovery and brain restoration. The clinic's longevity and expansion suggest sustained clinical utility, though the evidence base and mechanistic clarity for NAD+ infusions in longevity contexts remain limited.
Dizziness as Predictor of Dementia – Letter to the Editor
Dizziness and vestibular dysfunction emerge as measurable precursors to cognitive decline and dementia, suggesting that dysfunction in balance and spatial orientation systems may reflect broader neurological compromise before overt cognitive symptoms manifest. This finding repositions a common but often-overlooked symptom as a potential biomarker for early neurological risk.
The Effects of a Robot-Assisted Intervention Program on Cognitive Function and Psychosocial Outcomes in Community-Dwelling Older Adults: A Quasi-Experimental Study
An 8-week robot-assisted intervention program demonstrated measurable improvements in cognitive function and psychosocial outcomes among community-dwelling older adults. The findings support structured, interactive engagement as a practical approach to cognitive decline prevention in aging populations.
Spousal Discrepancies in Perceived Needs of People Living with Alzheimer’s Disease: A Mixed-Methods Study of Caregivers' Perspective Taking and Dyadic Communication
Caregivers of people with Alzheimer's disease frequently misalign with patients on identifying care needs, with discrepancies rooted in caregivers' limited perspective-taking capacity and dyadic communication patterns. This gap directly undermines care effectiveness and disease progression outcomes.
Who Bears the Burden? The Risk of Material Deprivation Among Adults Aged 50 and Older With Varying Caring Roles in Europe
Economic deprivation disproportionately affects adults over 50 in caregiving roles across Europe, with material hardship linked to reduced access to basic resources, adequate nutrition, and healthcare. This pattern reveals how financial stress compounds biological aging and constrains the conditions necessary for sustained health optimization.
Connecting fragmented aging research through the European Federation for Aging Research
The European Federation for Aging Research addresses fragmentation in gerontology research by establishing coordinated frameworks and data sharing across European institutions. Unified research infrastructure accelerates discovery in aging mechanisms and extends translational pathways to clinical intervention.
Resilience to Cardiac Aging in Greenland Shark Somniosus microcephalus
Greenland sharks exhibit extensive cardiac fibrosis, lipofuscin accumulation, mitochondrial damage, and oxidative stress—hallmarks of aging in other species—yet maintain healthy heart function across their 300-year lifespan. This dissociation between molecular aging markers and physiological health reveals evolved resilience mechanisms that preserve cardiac performance despite severe tissue-level deterioration.
ŌURA builds health AI stack with its latest acquisition spree
Ōura is assembling a health AI infrastructure platform through strategic acquisitions—integrating wearable data, metabolic tracking, clinical records, and performance analytics into a unified system designed to convert fragmented health signals into actionable guidance. This shift from passive tracking to real-time, AI-driven interpretation represents a fundamental change in how consumer health data could be organized and applied to longevity optimization.
AliveCor shrinks the ECG and speeds up diagnosis
AliveCor's Kardia 12L is a handheld, AI-assisted device that captures 12-lead ECG-quality cardiac data with simplified hardware and reduced setup time. The CE-marked system detects 35 cardiac conditions and reduces testing time by approximately one-third, extending hospital-grade diagnostic capacity into primary care, rural, and home settings.
Curve Biosciences advances AI blood diagnostics
Curve Biosciences has developed AI-powered blood diagnostics that detect organ-specific disease signals by analyzing epigenetic markers in circulating DNA, validated in a 1,482-patient cirrhosis study. This approach shifts chronic disease monitoring from episodic snapshots to continuous molecular tracking of organ stress and aging progression.
Omada Health study boosts quality of GLP-1 weight loss
A 12-week study of GLP-1 users receiving structured digital support achieved 1.8 times greater total weight loss, with twice the fat loss and nearly threefold greater muscle preservation compared to medication alone. The research demonstrates that weight loss quality—measured by body composition and functional outcomes—is a more meaningful indicator of health benefit than weight reduction alone.
It’s Springtime and the Rejuvenation Field Is Flourishing
The rejuvenation research field is advancing through improved diagnostic technology, clinical trial progress, and coordinated business-advocacy efforts. Non-invasive voice and gait biomarkers show promise for early detection of age-related diseases, particularly neurodegenerative conditions and infectious diseases, while the field strengthens its capacity to move discoveries into clinical application.
Longevity Day at NFC Summit Lisbon Announces Speaker Lineup
Longevity Day at NFC Summit Lisbon will convene researchers, clinicians, founders, and investors on June 4, 2026, organizing speakers across three thematic tracks: ancestral wisdom, contemporary science, and frontier biotechnology. The event represents a structured approach to advancing longevity science through interdisciplinary dialogue.
Perp Deficiency Induces Defective Negative Selection and Autoimmune Arthritis in Aged Mice
PERP protein deficiency impairs thymic negative selection—the process by which autoreactive T cells are eliminated during development—leading to accumulation of self-reactive CD4+ T cells and autoimmune arthritis in aged mice. This identifies a molecular mechanism linking defective immune tolerance to age-related autoimmunity.
Age‐Dependent Alterations of Chromosomal Passenger Complex Members During Implantation and Decidualization in the Mouse Uterus
Chromosomal passenger complex proteins show age-dependent dysregulation in the uterus during implantation and decidualization in aging female mice, with reduced cell proliferation markers and altered protein expression patterns that correlate with reduced implantation success. These findings identify a cellular mechanism underlying age-related fertility decline independent of ovarian function.
Brain Aging Mediating Heart Imaging‐Derived Phenotypes and Mental and Nervous System Disorders
Brain imaging from 33,573 participants reveals that accelerated brain aging mediates the relationship between cardiac structural changes and mental health disorders. Smoking and physical inactivity emerge as modifiable factors that influence this heart-brain-disorder pathway, suggesting intervention points in the progression toward age-related cognitive and psychiatric decline.
Merck and Eisai update Phase 3 renal cell carcinoma trial outcomes
A Phase 3 trial of experimental combination therapies for advanced renal cell carcinoma failed to meet primary endpoints for progression-free and overall survival compared to an approved two-drug regimen. This outcome underscores the complexity of optimizing immunotherapy combinations and the continued reliance on existing standard-of-care treatments for this indication.
Flagship launches Serif Biomedicines to develop modified DNA medicines
Flagship Pioneering launched Serif Biomedicines to develop Modified DNA medicines—a hybrid platform combining DNA and mRNA delivery with reduced immune activation and enhanced durability. The approach targets rare genetic diseases and immune reprogramming with preclinical evidence of tolerability and sustained gene expression in primates.
Interim data show RZ-001 responses in HCC
RZ-001, an RNA trans-splicing ribozyme, combined with atezolizumab and bevacizumab demonstrated objective response rates of 38.5–61.5% in hepatocellular carcinoma patients naive to systemic therapy, with no Grade 3+ adverse events attributed to RZ-001 alone. These interim results support continued development of this therapeutic approach for advanced HCC.
Innovative Vitality launches short-term personalized health program
Innovative Vitality launched a short-term membership program offering comprehensive biomarker analysis, body composition assessment, and personalized health planning for $549. The service targets individuals with persistent health concerns despite normal conventional lab results, providing a lower-commitment entry point to data-driven longevity optimization.
Senolytic Treatment With Fisetin Reverses Age‐Related Endothelial Dysfunction Partially Mediated by SASP Factor CXCL12
Fisetin, a plant-derived senolytic, reverses age-related endothelial dysfunction in aging mice by eliminating senescent endothelial cells and reducing the SASP factor CXCL12, which drives vascular dysfunction through oxidative stress and impaired nitric oxide production. This identifies a mechanistic pathway linking cellular senescence to cardiovascular aging and demonstrates functional recovery through targeted senolytic intervention.
Fasting and Caloric Restriction Activate an ADIOL‐NHR‐91‐Kynurenine Pathway Signaling Axis to Promote Healthspan
Fasting and caloric restriction activate ADIOL, a steroid hormone that signals through estrogen receptor β to reduce kynurenic acid in the nervous system and improve healthspan independent of lifespan extension. This mechanism appears evolutionarily conserved and remains effective even when ADIOL is supplemented late in life.
Reduction of glycation stress as a geroscience intervention: protocol for a pilot RCT in postmenopausal women
A pilot randomized controlled trial investigates whether reducing glycation stress—the accumulation of sugar-derived damage to proteins—can slow aging markers in postmenopausal women. Glycation is a hallmark of aging that accelerates decline across multiple physiological systems, making this intervention relevant to the practical toolkit of longevity medicine.
Inflammation’s statin moment edges closer
BioAge's NLRP3 inhibitor BGE-102 produced marked reductions in inflammatory biomarkers (hsCRP, IL-6, fibrinogen) in Phase 1 testing, positioning upstream inflammasome inhibition as a potential scalable approach to chronic inflammation management. This advances a field that has lacked convenient, long-term preventive options despite growing evidence that inflammation drives cardiovascular and age-related disease.
Cells that heal? New Parkinson’s trial sparks hope
A Phase II clinical trial of XS411, a stem cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease, has advanced based on encouraging Phase I results showing improved motor function and no adverse events. The approach represents a shift from symptomatic management toward cellular repair, potentially restoring function rather than merely masking decline.
Life Time brings VO₂ max and metabolic testing to the masses
Life Time's nationwide rollout of SpiroFit metabolic testing brings laboratory-grade VO₂ max and fuel-utilization data into mainstream fitness clubs, enabling members to identify metabolic inflection points and train with precision rather than assumption. This democratization of metabolic testing shifts a central longevity marker—previously available only to elite athletes—into accessible measurement for the general population.
Mesoblast invests in smarter cell therapies with new CAR tech deal
Mesoblast has licensed CAR technology to enhance its mesenchymal stromal cell therapies, enabling more precise targeting of inflamed tissues in autoimmune and inflammatory conditions. This represents a shift from broad biological effects to engineered precision at the cellular level, potentially improving both efficacy and speed of response in diseases like inflammatory bowel disease and lupus nephritis.
The Immune System Ages Differently in Men and Women
Research into age-related immune changes reveals sex-dependent trajectories, with females showing greater alterations in immune cell populations and autoimmune gene expression than males. This sex-specific immunosenescence pattern has direct implications for infection risk, cancer susceptibility, and chronic inflammatory disease across the lifespan.
Tozorakimab meets primary endpoint in Phase III miranda COPD trial
Tozorakimab, an IL-33-targeting monoclonal antibody, demonstrated statistically significant reduction in moderate-to-severe COPD exacerbations when added to standard inhaled therapy in a Phase III trial of 1,454 adults. This represents a potential therapeutic advance for patients with recurrent exacerbation history and establishes proof of mechanism across three pivotal trials.
Insilico forms longevity board to oversee AI aging research
Insilico Medicine established an oversight board combining pharmaceutical expertise with longevity science to accelerate AI-driven drug discovery targeting aging hallmarks. The initiative aims to translate experimental compounds into validated therapeutics across fibrosis, oncology, immunology, and metabolic disease.
Inbrain completes enrollment in first human graphene brain study
Inbrain Neuroelectronics completed enrollment of a first-in-human trial implanting graphene cortical interfaces in eight patients undergoing neurosurgical tumor resection, demonstrating favorable safety and high-resolution neural signal capture without device-related adverse events. This represents early validation of graphene-based brain-computer interfaces for clinical applications.
BioAge reports positive Phase 1 data for BGE-102
BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.
Multi‐Omics Reveals Mechanisms of Metabolic Rejuvenation in Aged Mice and Pre‐Frail Older Men by Losartan
Losartan, an angiotensin II receptor blocker, partially reversed aging-related metabolomic signatures in both aged mice and pre-frail older men, with effects dependent on functional angiotensin II receptors and correlating with improved survival in treated mice. The drug produced dose-dependent metabolic rejuvenation in humans and normalized age-related shifts in circulating metabolites, particularly lipids and amino acids.
Multi‐Omics Signatures of Organ Clocks in Biological Aging and Disease: A Conceptual Framework for Organ‐Specific Aging Clocks
Organ-specific aging clocks that integrate multiple molecular data types—genomics, epigenomics, transcriptomics, proteomics, and metabolomics—provide more accurate assessment of biological aging than single-measure approaches. This framework recognizes that individual organs age at different rates, offering a pathway to predict organ-specific disease risk and progression with greater precision.
The Mitochondrial NAD Transporter SLC25A51 in Adipocytes Regulates Adipose Tissue Mitochondrial Function and Systemic Metabolism During Aging
SLC25A51, a mitochondrial NAD transporter in fat cells, declines with age and directly regulates adipose tissue energy metabolism and systemic insulin sensitivity. Loss of this transporter accelerates metabolic disease phenotypes; its restoration protects against obesity and insulin resistance in aging.
Comorbid Alzheimer's Disease and Type 2 Diabetes Microbiota Shape Age‐Associated Gut–Brain Axis Profiles
Microbiota from elderly donors with both Alzheimer's disease and type 2 diabetes produce the most severe dysbiosis when transplanted into mice, suppressing hippocampal neurotrophic gene expression through loss of butyrate-producing bacteria and enrichment of pro-inflammatory taxa. This demonstrates a direct mechanistic link between comorbid metabolic and neurodegenerative disease states and gut-brain axis dysfunction.
Visual noise in augmented reality improves vision in age-related macular degeneration
Augmented reality presenting visual noise improves vision in age-related macular degeneration patients, likely by engaging neural plasticity mechanisms in the visual cortex. This represents a non-pharmaceutical approach to restoring functional vision in a degenerative condition affecting central sight.
Ordinal GWAS analysis of the frailty phenotype identified a novel locus at 12q22 that underscores the role of the neurological and immune systems
A genome-wide association study identified a novel genetic locus at 12q22 linked to frailty, implicating both neurological and immune system dysfunction in age-related decline. This finding suggests frailty operates through coordinated failure across defense and nervous system signaling rather than isolated organ dysfunction.
Energy Span reframes fatigue as early warning
Energy Span reframes fatigue as a quantifiable, systems-level signal of healthspan decline that emerges before conventional biomarkers shift into pathological ranges. This perspective bridges the gap between subjective experience and measurable biology, positioning energy as an early warning system reflecting mitochondrial function, metabolic flexibility, circadian rhythm, and autonomic regulation operating in concert.
GSK acquires 35Pharma in $950m deal, advancing PH drug
GSK acquired Montreal-based 35Pharma for $950 million, gaining HS235, a targeted pulmonary hypertension candidate that addresses vascular dysfunction while showing early signals of metabolic benefit—fat-selective weight loss, preserved muscle, and improved insulin sensitivity. The drug represents a shift toward precision mechanisms that reduce side-effect burden in chronic disease management.
Can AI outsmart Alzheimer’s? $6.2m grant fund says yes
A $6.2 million NIH grant funds AI-driven analysis of 1,800 Alzheimer's-linked genes to identify genetic targets upstream of amyloid pathology, shifting focus from symptomatic treatment to early-stage vulnerability. Current amyloid-targeting drugs slow progression at best; identifying genetic determinants of susceptibility may enable earlier, more precise intervention before neurodegeneration becomes symptomatic.
Hone Health adds DEXA scans to personalized longevity platform
Hone Health integrated clinical-grade DEXA scans into its personalized longevity platform, enabling physicians to assess body composition changes—muscle, fat, and bone density—alongside metabolic and hormonal data. This shift from reactive screening to proactive monitoring allows earlier detection of metabolic drift and interventions before functional decline.
Could osteoporosis meds prevent aneurysms?
Age-related mutations in blood-forming stem cells (clonal hematopoiesis) appear to drive aortic aneurysm progression through a bone-remodeling pathway hijacked in vascular tissue. Existing osteoporosis medications targeting this pathway slowed aneurysm growth in animal models, suggesting a repurposing opportunity for a condition currently lacking pharmacological interventions.
Rapamycin Might Blunt Exercise Response in Humans
A randomized, placebo-controlled trial in sedentary adults aged 65-85 found that weekly rapamycin (6 mg) blunted functional gains from a 13-week exercise program, with the placebo group showing greater improvements in chair-stand performance and related measures. The drug's 62-hour half-life likely prevented adequate recovery of mTORC1 signaling between training sessions, creating a pharmacokinetic conflict with exercise adaptation.
BioAge Reports Positive Phase 1 Data for BGE-102
BGE-102, a novel NLRP3 inhibitor, achieved profound and sustained reductions in high-sensitivity C-reactive protein (hsCRP) and multiple inflammatory biomarkers in Phase 1 trials, with 87% of obese participants with elevated inflammation reaching normalized hsCRP levels (<2 mg/L) at the lower 60 mg daily dose. This positions the compound as a potential best-in-class anti-inflammatory therapeutic for cardiovascular and metabolic disease prevention.
Preference for the Use of Home and Community-Based Services Among Older Adults With Hearing Loss in Rural China
Older adults with hearing loss in rural China underutilize home and community-based services, a gap that widens health disparities in this population. Understanding preferences and barriers to service access is essential for designing interventions that reach vulnerable populations where traditional healthcare infrastructure is limited.
Life Satisfaction Domains Among Older Adults: Patterns by Age, Gender, and Living Arrangement
Life satisfaction across health, financial, social, family, and personal domains varies meaningfully by age, gender, and living arrangement in adults over 65. Understanding these patterns informs targeted interventions addressing the psychosocial dimensions that predict longevity outcomes in aging populations.
AlzeCure completes Phase Ib study of ACD856
AlzeCure completed Phase Ib evaluation of ACD856, a candidate that modulates BDNF and NGF signaling across the blood-brain barrier. Preclinical evidence suggests neuroprotective and anti-inflammatory effects with potential disease-modifying capacity in cognitive decline and depression.
AB Science links masitinib to survival benefit in ALS trial
Masitinib, a tyrosine kinase inhibitor targeting microglial and mast cell activity, demonstrated a 5-year survival rate of 42.3% in ALS patients compared to historical benchmarks of 23.5%, with long-term survivors showing a median overall survival of 121 months versus 42 months predicted by standard models. This preprint evidence suggests a potential 79-month survival advantage and warrants confirmation in an upcoming randomized controlled trial.
UNC45B Reduction With Aging: A Myofiber‐Intrinsic Promoting Factor for Sarcopenia
UNC45B, a myosin chaperone protein, declines with age and is required to maintain fast-twitch muscle force and mass. Loss of UNC45B in skeletal muscle triggers a cascade of systemic effects: reduced contractile capacity precedes atrophy, followed by bone fragility, lower body temperature, and sleep disruption.
Telomere Dysfunction and Proteostasis Decline Define Distinct Pathways of Cellular Senescence in the Human Respiratory Tract
Proteostasis decline, not telomere dysfunction, emerges as the primary driver of cellular senescence in the respiratory epithelium during normal aging. This distinction has implications for understanding age-related respiratory decline and identifying intervention targets earlier than currently recognized.
Spatiotemporal Transcriptomics Characterizes Immune Microenvironment During Mouse Liver Aging
Aged livers accumulate exhausted CD8+ T cells predominantly in the portal vein zone, where periportal hepatocytes upregulate LPIN1 to promote immune dysfunction. This spatial immune dysregulation correlates directly with liver disease progression and identifies a therapeutic target for age-related hepatic pathology.
Mild cognitive impairment cases affect the predictive power of Alzheimer’s disease diagnostic models using routine clinical variables
Mild cognitive impairment (MCI) cases substantially reduce the predictive accuracy of Alzheimer's disease diagnostic models built on routine clinical variables. This finding challenges the assumption that standard biomarkers and clinical assessments alone can reliably stratify progression risk in early cognitive decline.
Cohort profile Davos Alzheimer’s Collaborative DAC Egypt Cohort
The DAC Egypt Cohort is a longitudinal study designed to identify early biomarkers and risk factors for Alzheimer's disease in an understudied Egyptian population, addressing a critical gap in dementia research outside Western cohorts. Early detection and prevention strategies depend on understanding how disease processes vary across genetic and environmental contexts.
Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study
A pilot study tracking epigenetic aging markers in patients receiving semaglutide for metabolic liver disease found that GLP-1 receptor agonists may slow biological aging rates independent of weight loss alone. The finding suggests semaglutide's effects extend beyond glycemic control to influence aging-related cellular mechanisms, with implications for understanding how pharmacological interventions affect the aging process itself.
Osteoboost raises $8m to scale bone wearable
Osteoboost has secured $8 million in funding to scale an FDA-cleared wearable device that delivers calibrated vibration therapy to address osteopenia, a condition affecting 44 million Americans currently managed with minimal intervention. The device represents a regulated approach to early-stage bone loss prevention in a market where pharmacological treatment remains absent and diagnostic management remains largely passive.
January AI enters Medicare App Library, reaches 69m+ patients
The CMS Medicare App Library now includes January AI, a data integration platform that translates fragmented health records into actionable insights for 69 million Medicare beneficiaries. This represents a structural shift toward patient-controlled healthcare where individuals access their own data and receive personalized guidance on immediate decisions—particularly relevant for older adults managing chronic disease.
How Inflammaging Is Linked to Epigenetic Aging
A Cell Genomics study demonstrates that age-related systemic inflammation (inflammaging) correlates with epigenetic aging as measured by established epigenetic clocks. This connection bridges two major aging hallmarks and suggests chronic low-grade immune activation reflects measurable changes in gene expression patterns independent of overt disease.
From hacks to health: why biohacking is growing up
The biohacking field is moving from supplementation and technological addition toward strategic simplification—recognizing that most modern interventions compensate for engineered-away baseline conditions like sunlight and movement rather than creating true upgrades. This shift reflects a maturing understanding that optimization requires knowing what to eliminate before adding tools.
Are global brands and employers longevity-ready?
Organizations across sectors remain structurally unprepared for demographic longevity, with the over-50 population underserved despite controlling significant spending power and representing a $67 billion market opportunity by 2035. Strategic repositioning toward healthspan optimization—rather than youth-centric models—is becoming a competitive and commercial imperative.
Maladaptive Inflammatory Signaling in Old Mice Impairs Colonic Regeneration by Promoting a Sustained Fetal‐Like Epithelial State
Aging impairs colonic regeneration through a maladaptive immune response characterized by excessive interferon-gamma production that triggers apoptosis in epithelial cells already primed in a fetal-like regenerative state. This dysregulation of immune-epithelial communication represents a critical mechanism by which aging compromises tissue repair capacity and increases vulnerability to infectious challenge.
Issue Information
Unable to analyze — the provided content contains only journal metadata (volume, issue, date) without article title, abstract, or substantive research findings. A complete article is required for evidence-informed analysis.
Seragon study shows SRN-901 extends median lifespan in mice
SRN-901, an oral combinatorial drug, extended median remaining lifespan by 33% in aged mice on a Western diet, with a 46% reduction in hazard of death and 70% attenuation of frailty progression. Multi-omics analysis indicated upregulation of DNA repair and metabolic pathways alongside suppression of inflammatory and oxidative stress responses.
Cala kIQ Plus cleared by FDA for action hand tremor
The FDA has cleared Cala kIQ Plus, a wearable neurostimulation device designed to reduce hand tremor in essential tremor and Parkinson's disease through peripheral nerve stimulation. The device incorporates adaptive calibration and variable waveforms to personalize tremor relief, with clinical data demonstrating improved responder rates and bilateral tremor control.
AliveCor launches CE marked Kardia 12L in Europe
AliveCor received CE Mark for the Kardia 12L, a portable 12-lead ECG system that reduces acquisition time by approximately 30 percent and uses AI to detect 35 cardiac conditions including myocardial infarction and ischemia. Early deployment across five European countries positions this device as an accessible diagnostic tool for detecting silent cardiac events before they become symptomatic.
Omada Health study finds greater fat loss, preserved muscle
A 12-week study of 245 adults with obesity found that Omada's GLP-1 Care Track program—combining pharmacotherapy with structured exercise, coaching, and digital tracking—achieved 1.8-fold greater weight loss and nearly threefold greater muscle preservation compared to GLP-1 monotherapy alone. This differential body composition outcome has direct implications for maintaining metabolic capacity and physical function during intentional weight reduction.
#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives
Current PSA-based prostate cancer screening protocols miss clinically significant cancers and fail to distinguish aggressive from indolent disease, reducing detection effectiveness. Modern biomarkers and imaging technologies enable earlier identification of aggressive tumors when intervention is most effective, fundamentally altering outcomes for men at risk.
Repurposing drugs for the prevention of vascular dementia using evidence from drug target Mendelian randomization
Mendelian randomization analysis of drug targets reveals limited repurposing opportunities for vascular dementia prevention. Beta-blockers targeting ADRB1 showed potential benefit, while ACE inhibitors demonstrated a possible risk signal, suggesting current cardiovascular drug strategies may not directly translate to dementia prevention.
Additional Cover
NAD+ preservation through dual mechanisms—inhibiting its depletion and enhancing its synthesis—delays cellular senescence while promoting musculoskeletal regeneration. This addresses a central constraint in aging: the body's declining capacity to maintain energy production and tissue repair as NAD+ levels fall with time.
Prostate cancer: a PSA on PSA
Prostate-specific antigen (PSA) screening remains an underutilized tool for early prostate cancer detection despite proven capacity to identify disease at more treatable stages. The clinical evidence supports selective screening in men at appropriate risk, yet implementation barriers persist in clinical practice.
Screened but Not Recognized: Cultural Gaps in Elder Abuse Identification in Rural China
This mixed-methods study reveals a significant disconnect between standardized elder abuse screening results and older adults' self-recognition of mistreatment in rural China, driven by cultural frameworks that normalize certain forms of harm. The finding underscores how population-wide screening protocols fail without accounting for cultural interpretation of what constitutes abuse.
Compounding Associations of Air Pollution and Heat Exposure With Cognitive Health Among Chinese Adults Aged 45+
Combined exposure to air pollution and heat accelerates cognitive decline in adults over 45, with compounding effects that exceed either exposure alone. This dual environmental stressor presents a significant mechanism of cognitive aging that demands attention in longevity planning.
Impact of Caregiver Burden on the Preferred Place for End-of-Life Care Among Older Adults in Japan: A Cross-Sectional Study
Caregiver burden significantly influences where older adults prefer to receive end-of-life care, with higher burden correlating to preferences for institutional rather than home-based settings. This finding reveals how social and psychological factors shape critical health decisions that affect both patient outcomes and family systems.
Global stagnation and misaligned priorities in BPH drug development: a 25-year landscape analysis of clinical trial registries
Benign prostatic hyperplasia drug development has stagnated over 25 years, with clinical trial pipelines showing minimal innovation and priorities misaligned with patient burden. This stagnation reflects a broader market failure in addressing age-related conditions that affect quality of life and functional independence in aging populations.
Engineered Stem Cells Become Lifelong Protein Factories
Researchers engineered hematopoietic stem cells to produce B cells that generate broadly neutralizing antibodies against HIV, malaria, and influenza. This approach creates long-lived protein factories capable of sustained antibody production, establishing a platform for durable immunity against pathogens that evade conventional vaccines.
New longevity drug SRN-901 shows 33% lifespan boost
SRN-901, a five-component oral combination therapy, demonstrated a 33% increase in median lifespan and 70% reduction in frailty progression in mice, with preserved physical function and reduced tumor incidence. The multi-pathway approach contrasts with single-target interventions, suggesting that aging requires simultaneous modulation of interconnected biological processes rather than isolated molecular manipulation.
Biotechs race to turn aging science into cell-based therapies
Multiple biotech companies are developing cell-based therapies targeting aging as an underlying condition rather than treating age-related diseases individually. The longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, driven by approaches using encapsulated cells, gene therapy, and stem cell platforms.
This AI ‘virtual lab’ wants to cut drug discovery to weeks
Helical has raised $10 million to build a shared computational platform that integrates AI models with reproducible workflows for drug discovery, addressing the critical gap between predictive capability and implementable decision-making in pharmaceutical R&D. The platform consolidates fragmented AI predictions into a unified system where results are traceable, validated, and actionable at scale.
Rubedo: the senolytic alchemist of aging biology
Rubedo Life Sciences has advanced RLS-1496, a first-in-class GPX4 modulator senolytic, through Phase 1 human trials based on the company's ALEMBIC AI platform for identifying senescent cell vulnerabilities. This represents a shift from repurposed compounds toward precision-targeted senolytics designed to eliminate dysfunctional cells while sparing healthy tissue.
Epicutis clinical study shows 77% improvement in skin appearance
Epicutis's Hydrobiome Serum, formulated with a patented TCP molecule, demonstrated 77% improvement in skin appearance over 8 weeks in a double-blind, placebo-controlled trial versus 56% in a comparator group. The formulation targets barrier integrity and hydration through membrane lipid signaling without broad immune suppression.
XellSmart launches multicenter Phase II trial of iPSC therapy
XellSmart initiated a Phase II trial of XS411, an iPSC-derived dopaminergic cell therapy for Parkinson's disease, following Phase I results demonstrating motor improvement, extended ON time, and graft survival without cell-related adverse events. This represents a critical advancement in regenerative approaches to neurodegenerative disease where conventional pharmacotherapy has limited disease-modifying capacity.
GNC adds MitoQ Pure and MitoQ NAD to The Drop
GNC has introduced MitoQ Pure and MitoQ NAD+ Dual Action supplements targeting mitochondrial function and oxidative stress reduction. Both formulations address energy production and cellular aging through distinct mechanisms—direct antioxidant support and NAD+ level optimization.
Life Time rolls out SpiroFit metabolic testing to country clubs
Life Time is deploying SpiroFit, a cordless wearable metabolic testing system, across 190 clubs to measure VO2 max and fuel utilization during exercise. The technology generates personalized heart-rate training zones with lab-grade accuracy, enabling members to optimize training intensity and metabolic efficiency.
Telomerase Knockout in Myeloid Cells Predisposes Mice to Foam Cell Formation, Dyslipidemia, Lung Fibrosis, and Cardiac Dysfunction
Telomerase (TERT) in myeloid cells prevents senescence and pro-inflammatory polarization through mechanisms independent of telomere length. Loss of myeloid TERT drives foam cell formation, dyslipidemia, pulmonary fibrosis, and cardiac dysfunction—establishing TERT as essential for preventing aging-associated multi-organ pathology.
Zfp462 Is a Key Mediator of Osteoblast Differentiation and Might Contribute to Age‐Related Bone Loss
Zfp462 is a transcriptional regulator essential for osteoblast differentiation and bone formation; aging reduces its expression through altered histone occupancy at its locus, providing a mechanistic explanation for age-related bone loss. Restoring Zfp462 activity or its associated transcriptional machinery represents a potential intervention pathway for senile osteoporosis.
AIRNA doses first patient in RNA-editing trial
AIRNA has initiated Phase 1 testing of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD), a genetic condition causing progressive lung and liver damage. Unlike permanent gene editing, RNA editing allows for repeated dosing and adjustment, positioning the approach as a reversible, titratable intervention aligned with how chronic disease and aging actually progress.
SIRIO Europe rolls out new habit-first longevity platform
SIRIO Europe launched Aeion, a habit-first longevity platform that prioritizes consistent daily rituals over complex protocols, addressing the persistent gap between longevity innovation and real-world adoption. The platform delivers eight supplement concepts through friction-reducing formats designed to support energy, mobility, cardiovascular function, and inflammatory aging management.
Targeting an Appetite Hormone Receptor for Stronger Muscles
Suppressing the ghrelin receptor (GHSR-1a) improves muscle function and reduces sarcopenia in aging mice through enhanced mitochondrial efficiency and altered muscle fiber composition. Pharmacological inhibition of this receptor produced similar benefits in older mice, suggesting a translatable approach to sarcopenia without extending lifespan.
Targeting an Appetite Hormone Receptor for Stronger Muscles
Inhibiting the ghrelin receptor (GHSR-1a) improves muscle strength, exercise capacity, and mitochondrial function in aging mice, reducing sarcopenia markers without extending lifespan. Pharmacological inhibition via PF-5190457 replicates these effects and represents a translatable therapeutic approach.
Your immune system now has a digital twin for longevity
A digital twin technology modeling immune system dynamics in real time enables predictive health outcomes rather than reactive assessment. This shift from static testing to continuous simulation represents a substantive advance in personalized longevity medicine.
Parkinson’s drug cuts OFF time in Phase 2
Solengepras, a once-daily investigational pill, reduced OFF-time periods in Parkinson's patients during Phase 2 trials by targeting GPR6 receptor signaling rather than dopamine replacement. This represents a shift toward systems-level rebalancing in Parkinson's treatment, with potential implications for motor control and sleep architecture in neurodegenerative disease management.
Associations Among Natural Disaster Exposure, Childhood Adversity, and Cognitive Functioning in Older Americans in the Health and Retirement Study
Natural disaster exposure in older adults correlates with reduced cognitive function, with effects significantly amplified in those who experienced adverse childhood events. This suggests cumulative stress across the lifespan shapes cognitive resilience in aging.
From Cultural Bias to Personal Beliefs: Latent Profiles of Ageism and Aging Self-Perceptions. Relationships With Mental Health and Cognitive Outcomes
Ageism and self-perceptions of aging cluster into distinct psychosocial profiles that correlate with cognitive performance and mental health outcomes in older adults. These profiles suggest that internalized attitudes toward aging—shaped by both cultural messaging and personal belief—measurably influence brain function and psychological resilience.
Mayo Clinic and Sana partner to advance Type 1 diabetes cell therapy
Mayo Clinic and Sana Biotechnology are collaborating to develop SC451, a hypoimmune-modified pancreatic islet cell therapy designed to restore glucose control in type 1 diabetes without requiring ongoing insulin or immunosuppression. The partnership establishes protocols for clinical delivery, patient selection, and monitoring to support Phase 1 trials beginning this year.
Mesoblast expands into CAR platform acquisition
Mesoblast acquired exclusive worldwide rights to a chimeric antigen receptor technology platform developed at Mayo Clinic to enhance its mesenchymal stromal cell therapeutic products. This expansion targets inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, lupus nephritis, and B-cell autoimmune conditions.
Hone Health integrates BodySpec DEXA scans into longevity OS
Hone Health integrated BodySpec DEXA scanning into its longevity platform, enabling real-time body composition, bone density, and metabolic rate assessment within clinical care plans. This shift moves bone health screening from reactive post-65 assessment to proactive longitudinal tracking across younger populations.
Ghrelin Receptor Deletion or Pharmacological Inhibition Improves Muscle Function in Aging Male Mice
Blocking the ghrelin receptor improves muscle endurance and mitochondrial function in aging mice without affecting muscle mass or lifespan. Both genetic deletion and pharmacological inhibition restore markers of mitochondrial renewal, suggesting this pathway is a viable therapeutic target for age-related muscle decline.
An Extracellular Matrix Aging Clock Based on Circulating Matrisome Proteins Predicts Biological Aging and Disease
Researchers developed a 14-protein aging clock from circulating extracellular matrix proteins that predicts biological age, distinguishes healthy from diseased states, and responds to rejuvenation interventions. This identifies ECM remodeling as a measurable biomarker and potential therapeutic target for age-related decline.
Endothelial Sirtuins and Mitochondrial Function Are Associated With Testosterone Status: Implications for Accelerated Vascular Aging in Middle‐Age and Older Men With Low Testosterone
Middle-aged and older men with low testosterone demonstrate reduced mitochondrial respiration and decreased SIRT3 expression in vascular endothelial cells, indicating accelerated vascular aging through impaired oxidative stress regulation. This mechanism links testosterone deficiency directly to cardiovascular disease risk through mitochondrial dysfunction.
Do Home- and Community-Based Services Reduce Elderly Care Needs and Family Caregiving Burden? Evidence From China
China's home- and community-based services pilot program reduced elderly care needs and family caregiving burden between 2008–2018, measured through longitudinal survey data. Organized access to professional support demonstrates capacity to shift care responsibility from informal family networks to structured systems, with direct implications for sustainable aging infrastructure.
p21 + TREM2 + senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease
Senescent macrophages expressing p21 and TREM2 accumulate with age and drive chronic inflammation and metabolic dysfunction in the liver. This identification of a specific senescent immune cell phenotype directly connects cellular aging to systemic metabolic decline and suggests a mechanistic target for interventions addressing age-related disease.
Genetic and molecular factors underlying human longevity and epigenetic aging
Epigenetic aging—the divergence between chronological age and biological age—emerges as a measurable marker influenced by both genetic predisposition and modifiable molecular factors. Understanding these mechanisms provides actionable insight into why some individuals age more slowly at the cellular level and how interventions targeting epigenetic signatures may extend healthspan.
Technogym and Google Cloud expand AI fitness
Technogym and Google Cloud are integrating generative AI into fitness platforms to shift from episodic workout protocols toward continuous, anticipatory health management scaled across populations. This partnership pairs four decades of physiological performance data with advanced language models to support adherence—a persistent barrier to preventive health outcomes—while embedding technology into the daily behavioral substrate where health decisions actually occur.
Hong Kong to host APAC longevity summit 2026
The 2026 APAC Longevity Medicine International Summit in Hong Kong will convene 2,000 researchers, clinicians, and policymakers to address the translation gap between geroscience discovery and clinical implementation. The event signals a maturation of the longevity field from laboratory breakthroughs toward systematic deployment of interventions at scale.
Lecanemab’s next phase: real-world treatment
Lecanemab is transitioning from controlled trials into real-world clinical practice, with Eisai presenting 14 studies on long-term outcomes, administration routes, and early intervention strategies. The data addresses whether cognitive benefits persist over extended periods and whether earlier detection and treatment can alter disease progression in what researchers term 'smoldering' Alzheimer's disease.
Workers rethink benefits: healthspan comes first
Sixty percent of UK workers now prioritize private health insurance over vacation time and life insurance, driven by concerns about access to timely medical care. The shift reflects a fundamental reorientation from managing consequences to preventing deterioration through early detection and treatment.
Vitamin C Alleviates Aging in Cynomolgus Monkeys
Iron accumulation drives a coordinated aging process called ferro-aging through oxidative damage and lipid peroxidation; vitamin C reverses these markers in primate models. This identifies iron metabolism and lipid oxidation as actionable targets in cellular senescence.
Vitamin C Alleviates Aging in Cynomolgus Monkeys
Iron accumulation drives a coordinated aging process termed ferro-aging, characterized by oxidative damage and cellular senescence across tissues. Vitamin C administration reversed aging markers and restored functional capacity in aged cynomolgus monkeys, suggesting a tractable intervention point in iron-dependent aging pathways.
Anavex highlights shared autophagy biology in autism and Alzheimer’s
Anavex presents evidence linking autism spectrum disorder and Alzheimer's disease through impaired autophagy and synaptic dysfunction, proposing that restoring cellular clearance pathways via their compound Blarcamesine may address both conditions. The finding connects neurodevelopmental and neurodegenerative disease through a shared cellular mechanism, with epidemiological data showing autistic adults face substantially elevated dementia risk.
Inclusion of People Aging With Disabilities in Sports and Leisure: An Environmental Scan on Opportunities and Capacity-Building Needs in Quebec, Canada
People aging with disabilities face significant barriers to leisure and sport participation despite evidence that such activities are determinants of healthy aging. This environmental scan of Quebec identifies capacity gaps and opportunities to increase inclusion in physical and social activities—a critical gap in gerontological practice.
International patent published for sirtuin 6 muscle therapy
Genflow Biosciences published a patent application for sirtuin 6 variants designed to prevent and treat muscle-mass loss, frailty, and sarcopenia through gene therapy. This approach targets a fundamental mechanism of age-related decline by restoring a protein variant associated with extended lifespan.
Remission Medical closes Series A to expand virtual rheumatology
Remission Medical raised Series A funding to scale virtual rheumatology services through health system partnerships and AI-driven workforce automation. The company addresses a significant access gap: over 54 million Americans with rheumatic diseases currently face two-month average waits for specialist evaluation.
RNA therapies research lists 80+ companies, 100+ drugs
A comprehensive market analysis catalogs over 80 RNA therapy companies and 100+ drug candidates across multiple modalities—mRNA, siRNA, antisense oligonucleotides, aptamers, and CRISPR approaches. The research examines development stages, delivery mechanisms, and commercial landscapes, with established players like Novartis and Arrowhead Pharmaceuticals advancing candidates across multiple therapeutic areas.
Cellular retinoic acid-binding protein 1, CRABP1, in thyroid gland aging
Cellular retinoic acid-binding protein 1 (CRABP1) regulates thyroid aging through vitamin A metabolism and retinoic acid signaling. Dysfunction in this protein correlates with thyroid senescence, positioning CRABP1 as a potential biomarker and intervention target for age-related thyroid decline.
Gut health, autoimmunity and the diet dilemma
Dr. Terry Wahls demonstrates that reframing chronic disease management from treatment to cellular infrastructure—with diet as the primary lever—can produce measurable functional recovery in progressive autoimmune conditions. Her work challenges the assumption that certain diseases are irreversible by restoring gut microbial balance and improving cell-level function through nutritional design.
FDA fast-tracks United Therapeutics’ bioengineered liver tech
United Therapeutics' bioengineered liver system, miroliverELAP, has received FDA Regenerative Medicine Advanced Therapy designation, accelerating its development as a bridge therapy for acute liver failure patients. The technology uses a decellularized pig liver scaffold seeded with human cells to provide extracorporeal organ support, potentially improving survival in the 30% of patients ineligible for or unable to access transplantation in time.
AI sharpens Alzheimer’s PET readouts
An artificial intelligence framework called interpretable adversarial decomposition learning (ADL) improves the clinical utility of Alzheimer's PET scans by filtering noise from disease signal, producing an ADAD score that correlates more closely with cognitive decline and neurodegeneration than traditional scoring methods. This advancement addresses a persistent gap between imaging findings and actual patient outcomes.
Alzheimer’s risk gene reveals hidden bone decline in women
APOE4, a major Alzheimer's disease risk gene, compromises bone quality in women through disruption of osteocytes—the long-lived cells responsible for maintaining bone microarchitecture—despite normal appearance on standard imaging. This finding suggests bone deterioration may serve as an early, detectable signal of neurodegenerative risk before cognitive symptoms emerge.
A Single Sauna Session Causes White Blood Cell Mobilization
A 30-minute sauna session at 73°C triggers acute mobilization of circulating white blood cells across all major subtypes—neutrophils, lymphocytes, and monocytes—without selective recruitment of specific immune populations. This transient spike in immune surveillance capacity may represent a physiological mechanism underlying the epidemiological associations between regular sauna use and reduced cardiovascular disease, stroke, dementia, and all-cause mortality risk.
A Single Sauna Session Causes White Blood Cell Mobilization
A single 30-minute sauna session at 73°C triggers a transient increase in circulating white blood cells, with neutrophils and lymphocytes rising immediately post-session and returning to baseline within 30 minutes. This mobilization effect suggests a mechanism through which regular sauna use may confer documented cardiovascular and longevity benefits.
John Hancock introduces longevity readiness tool
John Hancock has launched a personalized longevity readiness assessment tool developed with MIT AgeLab that scores individuals across eight life domains—health, finance, care, housing, daily activities, community, life transitions, and social connection. The tool addresses a critical gap in longevity planning: most interventions focus on extending lifespan rather than preparing people psychologically, socially, and practically for the reality of extended years.
Frailty and Brain Myelin Across Adulthood: Multimodal MRI Insights From the BLSA
Frailty, measured by a validated Frailty Index, correlates with reduced myelin content across white matter tracts in adults from age 22 to 94, with the strongest associations in long-range projection fibers. This multimodal MRI evidence suggests myelin degradation may represent a neural substrate of systemic aging and physiological vulnerability.
Single‐Cell Profiling Reveals Distinct Immune Communication Networks in Centenarians and Elderly Controls
Single-cell immune profiling distinguishes centenarians from age-matched controls through divergent intercellular communication patterns: healthy aging shows reinforced regulatory signaling supporting cytotoxicity and immune surveillance, while standard aging exhibits self-amplifying senescence signals linked to immune exhaustion. This immune remodeling signature may explain exceptional longevity phenotypes.
Clearance of Senescent Cells by BCLXL‐PROTAC: A Novel Approach to Treat COPD?
BCL XL-PROTAC, a senolytic agent, selectively eliminates senescent cells in COPD airway tissue while promoting proliferation of healthy cells. This approach addresses a core driver of age-related lung disease and suggests a therapeutic pathway for restoring lung cell function in COPD patients.
Single‐Nucleus RNA Sequencing Reveals Muscle Fiber Cell Heterogeneity During Human Skeletal Muscle Aging
Single-nucleus RNA sequencing of vastus lateralis muscle from centenarians reveals a fundamental transcriptional reorganization characterized by a shift from metabolically robust fiber states to dysfunctional states accompanied by denervation and fatty infiltration. FAP-derived BMP and Laminin signaling emerges as a key driver of age-related muscle dysfunction, establishing specific molecular pathways amenable to therapeutic targeting.
Cell Type‐Specific Expression of p16, p21, and p53 Reveals Age‐Dependent Glial Senescence in the AppNL‐G‐F Mouse Model of Alzheimer's Disease
Microglial and astrocytic cells in an Alzheimer's disease mouse model exhibit progressive senescence linked to amyloid pathology, while neurons remain unaffected. This cell-type-specific senescence signature identifies glial cells as primary targets for senescence-directed therapeutic intervention in Alzheimer's disease.
Acid–Base Dysregulation Links Aging Metabolism to Frailty
Chronic acid accumulation from aging and stress depletes the body's buffering capacity, disrupting communication between physiological systems and driving frailty through impaired energy metabolism. This acid-base dysregulation mechanism unifies existing frailty models and identifies diet, exercise, and buffering strategies as therapeutic targets.
Living With Pride in Later Life: Minority Stress, Stigma, and Well-Being Among LGBTIQ+ Older Adults in Spain
LGBTIQ+ older adults in Spain experience measurable impacts on psychosocial well-being from minority stress and stigma, with social support emerging as a critical moderating factor. Understanding how social positioning and perceived discrimination influence mental health trajectories in aging populations has direct relevance to personalized longevity strategies.
The retina-body axis: proteomic mechanisms linking oculomics and clinical traits in a female aging cohort
Retinal protein signatures correlate with systemic aging markers and clinical traits in women, establishing the eye as a window into whole-body physiological age. These oculometric measures may enable earlier detection of aging-related dysfunction across multiple organ systems.
Astrocyte-based CAR immunotherapy against Alzheimer’s disease
Engineered astrocytes equipped with chimeric antigen receptor technology can target amyloid-β and tau pathology in Alzheimer's disease models, offering a cell-based immunotherapy approach that addresses hallmark neuropathological features. This represents a distinct mechanistic strategy for modulating neuroinflammation and clearing pathogenic protein aggregates implicated in cognitive decline.
Longevity market to hit $67b by 2035 due to rising aging concerns
The global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven by a shift from reactive disease treatment to preventive health monitoring and consumer-directed self-management. This expansion reflects a fundamental change in how aging is approached—not as an inevitable decline to manage, but as a process to optimize through early detection, biological measurement, and strategic intervention.
Alzheon pushes oral Alzheimer’s pipeline forward
Alzheon has dosed the first healthy volunteers in a Phase 1 trial of ALZ-507, an oral Alzheimer's candidate designed to prevent amyloid clumping and correct APOE4 dysfunction. The drug represents a shift toward earlier intervention and simplified delivery in a disease where accessibility and tolerability have historically limited treatment adoption.
Function acquires Getlabs to scale at-home testing
Function's acquisition of Getlabs removes logistical friction from routine health testing by bringing blood draws directly to patients' homes and offices. This operational change addresses a fundamental barrier to consistent health monitoring—the primary prerequisite for sustained, data-driven health optimization.
Parkinson’s drug may backfire, study finds
COMT inhibitors, commonly prescribed alongside levodopa for Parkinson's disease, reduce levodopa efficacy by altering gut bacterial composition rather than through direct pharmacological interaction. This microbiome-mediated effect explains variable patient responses to the same medication regimen and highlights an overlooked mechanism in drug interaction.
Women-only longevity retreat debuts in Bali
A women-focused wellness retreat in Bali is repositioning around functional longevity, moving beyond spa-based pampering toward practical health optimization. The model addresses a market gap by making longevity science accessible to women through experiential protocols rather than clinical metrics.
Why Fast-Cycling Skin Cells Decrease With Age
Fibulin-5, an extracellular matrix protein that declines with age, regulates fast-cycling skin cell populations through the YAP signaling pathway. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of regenerative cell populations and compromised dermal-epidermal integrity, suggesting this protein may be central to maintaining skin renewal capacity across the lifespan.
Why Fast-Cycling Skin Cells Decrease With Age
Fibulin-5, an extracellular matrix protein that declines with age, maintains populations of fast-cycling skin cells through YAP signaling. Mice lacking fibulin-5 exhibit accelerated skin aging phenotypes, including loss of fast-cycling cells and compromised epidermal-dermal junction integrity, mirroring natural aging processes.
Positive Phase 2 data show Solengepras benefits in Parkinson’s
Solengepras, a GPR6 inhibitor administered orally once daily, reduced OFF time and improved sleep in Phase 2 Parkinson's trials without directly modulating dopamine. Phase 3 data will determine whether this non-dopaminergic approach offers meaningful clinical benefit in motor fluctuations.
Longevity market projected to hit $67 billion by 2035
The global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven by increased prevalence of age-related disease, adoption of preventive healthcare, and advances in regenerative medicine, genomics, and biomarker technologies. This expansion reflects a structural shift toward intervention before disease manifests.
Mesoblast receives IND clearance to proceed to registrational trial
Mesoblast received FDA clearance to advance Ryoncil, a mesenchymal stromal cell therapy, into a registrational trial for Duchenne muscular dystrophy in children aged 5-9. The therapy targets the inflammatory cascade underlying DMD progression, with time-to-stand at 9 months as the primary efficacy endpoint.
Eisai to present Lecanemab data at AAN meeting
Eisai will present multiple datasets on Lecanemab, an anti-amyloid monoclonal antibody for Alzheimer's disease, at the American Academy of Neurology Annual Meeting in April 2026. The presentations include mechanistic data on amyloid-β reduction, real-world safety and efficacy outcomes, long-term follow-up findings, and clinical implementation guidance.
Microcap produces anti-aging protein from encapsulated cells
Klothonova is developing an encapsulated cell therapy designed to restore circulating α-Klotho, a protein that declines with age and influences cardiovascular, renal, and cognitive function. The approach uses genetically modified cells housed in a biocompatible capsule to sustainably produce the protein, addressing a mechanism implicated in multiple age-related conditions.
APLMS and Kitalys to Host Healthy Longevity in Hong Kong
The 2026 Asia-Pacific Healthy Longevity International Summit will convene over 2,000 global leaders in Hong Kong to advance clinical implementation of longevity science. The event reflects a strategic shift from discovery toward translating research into scalable, real-world health interventions across healthcare systems.
APLMS and Kitalys to Host Healthy Longevity in Hong Kong
The Asia-Pacific Longevity Medicine Society and Kitalys Institute will host a 2026 summit in Hong Kong to translate longevity research into clinical practice at scale. The event brings together 2,000+ leaders across medicine, geroscience, digital health, and policy to establish standards and delivery models for personalized longevity interventions.
#387 – AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field
Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.
Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging
Caloric restriction reduces circulating C3a, a complement protein that drives inflammaging in aged tissues. This identifies a specific immunometabolic pathway through which moderate energy restriction extends healthspan in humans.
Research Worth Sharing, April 2026 Edition
Four emerging research areas—paternal exercise effects on offspring via sperm signaling molecules, mRNA vaccine applications in cancer treatment, non-invasive sensory stimulation for neurodegeneration, and autonomic nervous system dysfunction as a common aging mechanism—establish mechanistic pathways through which upstream interventions influence downstream health outcomes across generations and disease states.
Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide
Temozolomide-induced senescent glioblastoma cells exhibit dynamic morphological states with distinct survival mechanisms and drug sensitivities. This heterogeneity and plasticity have direct implications for how chemotherapy resistance develops and why combination senotherapeutic strategies may be necessary to prevent tumor recurrence.
Education platform targets longevity knowledge gap
A curated education marketplace has launched to address the fragmentation in longevity learning, creating a vetted platform for clinicians, practitioners, and consumers to access high-quality programs that bridge scientific discovery and clinical practice. The platform recognizes that rapid advancement in longevity science has outpaced the development of standardized, accessible training infrastructure.
Mitrix moves mitochondria into the clinic
Mitrix Bio has reported preliminary Phase 1 safety data from mitochondrial transplantation in two older adults with no observed adverse effects, while simultaneously launching clinics offering the intervention under Right to Try frameworks. This represents a transition from preclinical work to early clinical deployment, though data density remains limited relative to narrative momentum.
NeuroTherapia clears Phase 2a in novel Alzheimer’s treatment
NeuroTherapia's oral Alzheimer's candidate NTRX-07 completed Phase 2a with safety clearance and early signals suggesting effects on neuroinflammation, the chronic immune dysregulation increasingly recognized as a major driver of cognitive decline. The drug targets brain inflammation rather than amyloid alone, representing a shift toward multi-system disease understanding.
Supernatural gives longevity a storefront in Toronto
Supernatural, a Toronto retail concept, packages longevity and health optimization as an accessible consumer experience, partnering with functional medicine to create a diagnostic-led pathway that lowers entry barriers while maintaining measurable outcomes. This model addresses the gap between longevity science and sustained behavioral adoption by integrating recovery technologies, personalized testing, and ongoing clinical support into an intuitive lifestyle environment.
AliveCor brings AI heart diagnostics to Vietnam
AliveCor's Kardia 12L portable AI-powered ECG system has gained regulatory approval in Vietnam, enabling distributed cardiac diagnostics in a country where cardiovascular disease accounts for 33% of deaths. The device reduces acquisition time by approximately 30% and simplifies the testing process, addressing both access barriers and workflow bottlenecks in healthcare systems managing high patient volumes.
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
Overexpression of somatostatin, a neuropeptide normally produced by neurons, reduces microglial activation and amyloid-β burden while improving cognitive function in an Alzheimer's disease mouse model. The finding identifies a previously untested communication pathway between neurons and immune cells that becomes dysregulated in the disease and offers a target for existing pharmaceuticals.
Affecting a Signaling Pathway Alleviates Alzheimer’s in Mice
Somatostatin overexpression in neurons reduces microglial activation and inflammatory signaling while enhancing amyloid-β clearance in an Alzheimer's mouse model. Existing drugs targeting this pathway suggest translational potential for addressing neuroinflammation in cognitive decline.
Longeveron gains Chinese patent for mesenchymal cell potency assays
Longeveron secured a Chinese patent for mesenchymal stem cell potency assays, extending its intellectual property protection through 2041. This standardization of cell quality assessment is foundational for regulatory approval of cell-based therapies, particularly as the company advances laromestrocel in aging-related frailty and cardiac disease.
Mesoblast receives IND clearance for registrational trial of Ryoncil
Mesoblast has received FDA clearance to conduct a registrational trial of Ryoncil, an allogeneic mesenchymal stem cell therapy, in pediatric Duchenne muscular dystrophy patients aged 5-9 years. The trial will assess whether the therapy's anti-inflammatory properties can preserve muscle function and slow disease progression in a population with limited treatment options.
CorTec receives FDA breakthrough device designation
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
Coya Therapeutics publishes study linking biomarkers to ALS outcomes
Three serum biomarkers—4-HNE, LBP, and NfL—are elevated in ALS patients and correlate with disease progression and survival outcomes. This biomarker profile may enable earlier detection and prognostic stratification, informing treatment timing and patient selection for immunomodulatory interventions.
Integrin‐Binding Matricellular Protein Fibulin‐5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging
Fibulin-5, an extracellular matrix protein that declines with age, maintains epidermal stem cell function by activating YAP signaling through integrin binding. Loss of fibulin-5 reproduces age-associated changes in skin stem cell populations, identifying a molecular mechanism linking extracellular environment degradation to cellular aging.
The Mediating Role of Job Satisfaction Between Psychological Capital and Neglect Among Geriatric Nursing Assistants in Nursing Homes in China: A Cross-Sectional Study
Job satisfaction among geriatric nursing assistants mediates the relationship between psychological capital and neglectful care practices in Chinese nursing homes. This finding identifies a modifiable factor directly linked to quality of care and resident health outcomes in institutional settings.
Prevalence and Impact of High-Impact Chronic Pain on Subjective Cognitive Decline: The Moderating Role of Age in the NHIS Dataset
High-impact chronic pain is associated with subjective cognitive decline, with age acting as a moderating factor. This relationship has implications for understanding how persistent pain states interact with cognitive aging and longevity outcomes.
Prevalence and Social Support Networks of Underrepresented Caregivers: Sandwich, Millennial, Non-kin, and Male Caregivers
Caregiving prevalence varies significantly across underrepresented populations—millennials, non-kin caregivers, males, and sandwich caregivers—with distinct social support network patterns. Understanding these demographic variations is essential for designing interventions that address caregiver burden and health outcomes across diverse populations.
Human cGAS Drives LINE‐1 Transcriptional Activation to Trigger MAVS‐Dependent Cellular Senescence
Human cGAS activates LINE-1 retrotransposon transcription through upregulation of CTCF and RUNX3, triggering cellular senescence via MAVS-dependent RNA sensing. This human-specific pathway reveals a mechanism linking genomic surveillance to accelerated cellular aging, with direct implications for understanding senescence in aging and age-related disease.
Biological sex shapes divergent trajectories of immune aging
Single-cell profiling of nearly 1,000 individuals demonstrates that immune aging follows distinct cellular and transcriptional trajectories between sexes, with female participants showing more pronounced cellular and molecular remodeling than males. This finding reveals that sex-based differences in immune function are not uniform across aging and must inform how we assess and support immune resilience across the lifespan.
Single-cell analysis of the human immune system reveals sex-specific dynamics of immunosenescence
Single-cell immune profiling across nearly 1,000 adults reveals sex-specific patterns of immune aging, with females demonstrating more extensive age-related remodeling of immune function. These findings establish a biological basis for observed sex differences in inflammatory disease prevalence and infection susceptibility across the lifespan.
Fountain Life adds APEX to premium longevity program
Fountain Life launched APEX, a year-long premium membership that integrates full-body diagnostic screening with functional movement assessment and VO₂ max testing to shift from episodic health snapshots to continuous, performance-focused monitoring. This model addresses a gap in longevity medicine: most preventive programs measure biomarkers and imaging but neglect movement quality and cardiorespiratory capacity—the actual mechanics of aging and functional independence.
Erectile dysfunction drugs and longevity
PDE5 inhibitors, established drugs for erectile dysfunction, are attracting early interest in longevity medicine for their capacity to improve vascular function and tissue resilience through nitric oxide signaling—not by targeting root causes of aging, but by supporting system performance under the stress of accumulated damage.
NADMED backs Cleveland Clinic transplant study
Cleveland Clinic's awarded research uses redox biology—specifically NAD and NADH measurement—to assess metabolic viability of donor organs during the ischemic period before transplantation. This work translates longevity science concepts into actionable clinical tools for organ quality assessment and transplant outcomes.
Merck bets on antibody startup Infinimmune for longevity edge
Merck's $838 million collaboration with Infinimmune represents a strategic shift toward human-centered antibody discovery, using memory B cells as a biological library to accelerate therapeutic candidate identification from weeks to months rather than years. This approach addresses a fundamental bottleneck in drug development—finding viable starting candidates—and signals Big Pharma's recognition that speed and biological fidelity, not just innovation volume, are competitive advantages in longevity medicine.
Annovis traces buntanetap’s road to Alzheimer’s
Buntanetap, Annovis Bio's investigational therapy, targets multiple neurotoxic proteins implicated in Alzheimer's and Parkinson's disease rather than a single pathway. This multi-target approach reflects an emerging recognition in longevity science that neurodegeneration involves systemic breakdown across multiple mechanisms, not isolated protein pathology.
A Combination NAD+ Treatment Has Benefits for Mice
Researchers demonstrated that combining NAD+ precursor supplementation (NMN) with apigenin, a compound that reduces NAD+ degradation, restores muscle function and bone structure in aged mice. This dual-mechanism approach addresses both NAD+ availability and preservation, with relevance to human aging given prior clinical evidence for NAD+ precursors in metabolic and respiratory function.
A Combination NAD+ Treatment Has Benefits for Mice
Researchers demonstrated that combining NMN supplementation with apigenin—which inhibits NAD+ breakdown—restores muscle function and bone structure in aged mice. This dual approach addresses both supply and preservation of NAD+, a critical coenzyme in cellular energy metabolism and stress resistance.
Scala Biodesign lands $16m to speed protein R&D
Scala Biodesign raised $16 million to scale ScalaOS, a computational platform that accelerates protein design for therapeutics by replacing iterative laboratory trial-and-error with physics-based modeling and AI. Early adoption by nine of the world's top 20 pharmaceutical companies signals that this infrastructure addresses a fundamental bottleneck in biologics development.
Single‐Cell Profiling Reveals RAB13+ Endothelial Cells and Profibrotic Mesenchymal Cells in Aged Human Bone Marrow
Single-cell analysis reveals that aging bone marrow undergoes distinct cellular remodeling: endothelial cells develop prothrombotic and mitochondrial dysfunction, while a novel RAB13+ arterial endothelial subset emerges alongside expansion of profibrotic mesenchymal cells. These cellular shifts directly impair the marrow's capacity to support healthy blood cell production and tissue maintenance, establishing specific molecular targets for intervention.
[Comment] Severe infections consistently linked to dementia?
Severe infections show a persistent association with dementia risk that remains significant even after adjusting for frailty and age-related conditions, suggesting the connection operates through mechanisms independent of pre-existing disease burden. This finding extends prior research and points toward infection-related pathways that directly influence cognitive decline.
[Comment] Point-of-care technology and lung ultrasound in ageing societies: towards integrated respiratory care beyond hospital walls
Point-of-care lung ultrasound and integrated respiratory monitoring technologies enable early detection of age-related pulmonary decline outside hospital settings, shifting care delivery toward prevention and functional preservation in aging populations. This decentralization of respiratory assessment addresses a critical gap in longevity care: the ability to identify declining respiratory capacity before symptomatic disease emerges.
[Articles] The role of frailty and comorbidities in severe infections and the risk of dementia: a prospective, multicohort, observational study
Severe infections carry independent dementia risk beyond what frailty and comorbidities explain, suggesting infection-related mechanisms directly contribute to cognitive decline. This identifies a modifiable pathway distinct from typical aging trajectories.
[Articles] Extended use of point-of-care technology by acute community nurses during in-home assessment of older adults with potential acute respiratory conditions: a parallel-group, open-label, randomised controlled trial
Extended point-of-care testing in community nurse assessments of older adults with acute respiratory conditions did not reduce hospital admissions compared to standard care. The additional diagnostic capability appeared to have minimal influence on clinical decision-making pathways.
Brimonidine Therapy for Protection From Noise‐Induced Hearing Loss
Brimonidine protects against noise-induced hearing loss in mice by suppressing glutamate synthesis and reducing excitotoxicity, with protective effects persisting into old age. Early intervention during acoustic trauma exposure may prevent accelerated age-related hearing decline.
A Circadian Trough in Glucocorticoid Signaling Is Essential for Bone Health in Mice
Circadian glucocorticoid rhythm—specifically the daily trough when cortisol signaling drops—is essential for bone formation and structural integrity. Flattening this rhythm induces osteoporosis even without elevated overall cortisol, and reinstating the trough at its natural circadian timing prevents bone loss.
NeuroTherapia completes Phase 2a trial of NTRX-07 in Alzheimer’s
NeuroTherapia completed a Phase 2a trial of NTRX-07 in 48 Alzheimer's patients, demonstrating safety and tolerability with no serious adverse events in the treatment group. Exploratory endpoints showed encouraging trends toward cognitive stabilization and favorable biomarkers of neuroinflammation, warranting further investigation in larger trials.
Airna doses first patient in Phase 1 trial of AIR-001 for AATD
Airna initiated a Phase 1 trial of AIR-001, an RNA-editing therapeutic designed to correct the genetic mutation underlying alpha-1 antitrypsin deficiency by restoring functional AAT protein production. This approach addresses a monogenic disorder affecting both pulmonary and hepatic function, representing a mechanistic advance in treating a condition with significant longevity impact across multiple organ systems.
AliveCor expands AI 12-lead cardiac diagnostics to Vietnam
AliveCor's Kardia 12L, an AI-powered portable 12-lead electrocardiogram system, has secured regulatory registration in Vietnam to enable hospital-grade cardiac diagnostics at point of care. The device reduces acquisition time by approximately 30% and simplifies electrode setup, allowing earlier detection of arrhythmias, myocardial infarction, and cardiac ischemia in community and outpatient settings.
Life Biosciences secures $80 million Series D financing
Life Biosciences closed $80 million in Series D funding to advance ER-100, a Phase 1 therapeutic candidate using partial epigenetic reprogramming to restore cellular function in age-related eye disease. The approach targets fundamental mechanisms of cellular aging across multiple disease indications.
United Therapeutics receives RMAT designation for Miroliver ELAP
United Therapeutics received FDA Regenerative Medicine Advanced Therapy designation for Miroliver ELAP, a bioengineered external liver assist device combining a decellularized porcine scaffold seeded with human endothelial and hepatic cells. This designation accelerates development of a bridge therapy for acute liver failure, where 30% of patients currently die due to organ shortage despite potential for spontaneous recovery.
Dyno Therapeutics license exercised by Astellas for muscle delivery
Astellas exercised a licensing option for a Dyno Therapeutics engineered AAV capsid designed for skeletal muscle gene delivery, marking validation of AI-driven capsid engineering for tissue-targeted viral vectors. The technology addresses a fundamental limitation in gene therapy: achieving efficient delivery to specific tissues while maintaining manufacturability.
Cognito partners to stop using ‘dementia’ in communications
Cognito Therapeutics has committed to eliminating the term 'dementia' from all communications in partnership with the Initiative to Change the D-Word, prioritizing patient-centered language that reduces stigma and supports earlier recognition of cognitive decline. This linguistic shift reflects a broader movement toward precision in how cognitive pathology is discussed and treated.
Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza
Senolytic treatment with ABT-263 reduced lung and intestinal inflammation and prevented long-term pulmonary damage in aged mice infected with influenza, though it did not reduce viral replication itself. The findings indicate that pre-existing senescent cells drive inflammatory pathology rather than viral control, suggesting a therapeutic target for improving outcomes in older adults.
Physical Fitness Is Negatively Associated With DNA Methylation‐Based Risk of Aging‐Related Diseases
Physical fitness metrics correlate with DNA methylation patterns of circulating proteins, revealing molecular pathways that link muscular strength, aerobic capacity, body composition, and cognitive function to reduced risk of age-related diseases. This molecular mapping enables patient-level disease risk stratification based on combined fitness and epigenetic measurements.
Correlation between frailty status, surgical access, and outcomes in older adults with valvular heart disease undergoing cardiac surgery
Frailty status in older adults with valvular heart disease significantly predicts surgical outcomes and mortality risk independent of traditional cardiac metrics. Surgical access method (minimally invasive versus open) interacts with frailty to influence recovery and functional decline, establishing frailty assessment as critical for preoperative risk stratification in this population.
Plasma hippuric acid as a marker of frailty influenced by dietary fruit and vegetable consumption: longitudinal analysis in Italian cohorts of older adults
Plasma hippuric acid, a metabolite derived from polyphenol metabolism, correlates with frailty status in older adults and is significantly influenced by fruit and vegetable consumption. This relationship suggests a measurable biochemical pathway through which dietary polyphenols may modulate age-related functional decline.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.
Life Bio’s Trial: Is the FDA Warming to Rejuvenation?
Life Biosciences' ER-100, a cellular reprogramming therapy, has received FDA clearance for human trials targeting optic nerve disorders. The trial represents a regulatory shift toward rejuvenation-based approaches, potentially positioning cellular age-reversal technologies within mainstream clinical frameworks rather than relegating aging to inevitability.
Peloton named Movement Partner for The Longevity Show 2026
The Longevity Show 2026 has partnered with Peloton to embed structured movement into longevity programming through experiential sessions and community-based activities. This signals a strategic pivot from laboratory biomarkers toward operationalizing the behavioral and adherence mechanisms that translate longevity science into sustained practice.
WHOOP’s $575m raise backs always-on health
WHOOP has secured $575 million in Series G funding at a $10.1 billion valuation, positioning itself as a continuous health monitoring platform that translates physiological data into actionable guidance. The funding reflects investor confidence that longevity platforms embedding real-time health tracking into daily life can shift healthcare from reactive to proactive intervention.
Tiny gene reveals splicing’s role in disease
Researchers mapped functional consequences of hundreds of mutations in RNU4-2, a 145-base non-coding RNA gene within the spliceosome, linking splicing dysfunction to neurodevelopmental disorders affecting approximately 100,000 individuals globally. This work establishes a systematic framework for interpreting non-coding variants and refines genomic diagnosis beyond association to functional mechanism.
Life Biosciences lands $80m to push cell reset therapy
Life Biosciences secured $80 million to advance ER-100, the first partial epigenetic reprogramming therapy entering human trials, designed to restore cellular function in age-damaged neurons. This represents a shift in aging intervention from symptom management toward addressing the underlying cellular decline that drives multiple age-related diseases.
Epia Neuro debuts with stroke-focused BCI
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
The Timing of Meals Matters for Biological Aging
Meal timing significantly influences biological aging rates, with earlier first meals (before 8 a.m.) and last meals between 3 p.m. and 7 p.m. associated with slower aging in heart, liver, and whole-body measures. The relationship is nonlinear and depends on age, sex, caloric intake, and organ-specific responses.
The Timing of Meals Matters for Biological Aging
Meal timing correlates with biological aging rates across multiple organs, with optimal outcomes occurring when the first meal is consumed before 8 a.m. and the last meal between 3 p.m. and 7 p.m., while extended feeding windows and late first meals accelerate aging markers in the heart and liver. This relationship varies substantially by age, sex, and metabolic health status, suggesting meal timing functions as a modifiable variable in aging trajectories.
Givaudan showcases AI-powered ingredient demos with Haut.AI
Givaudan and Haut.AI are demonstrating AI-powered skin visualization tools at an industry conference, allowing consumers to preview how active ingredients affect visible skin parameters. The partnership emphasizes personalized prediction of ingredient effects through generative simulation technology.
Cognition Therapeutics to update investors at Needham virtual conference
Cognition Therapeutics will present clinical progress on zervimesine (CT1812), a candidate for Alzheimer's disease and dementia with Lewy bodies, at the Needham Healthcare Conference in April 2026. The compound has demonstrated efficacy signals in Phase 2 studies with acceptable tolerability, positioning it for late-stage development in DLB psychosis.
Alzheon doses first subject in Phase 1 of ALZ-507
Alzheon has initiated Phase 1 trials of ALZ-507, an oral small molecule designed to inhibit neurotoxic amyloid oligomer formation and correct APOE4 dysfunction. The compound demonstrates favorable preclinical safety and pharmacokinetic profiles supporting once-daily dosing, with Phase 2 studies planned across Alzheimer's disease, Down syndrome-associated AD, and cerebral amyloid angiopathy.
NeuroSense granted Brazilian patent for PrimeC composition
NeuroSense secured Brazilian patent protection for PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib designed for neurodegenerative diseases including ALS and Alzheimer's. The patent, valid through 2042, follows U.S. and Australian approvals and supports ongoing Phase 3 development based on positive Phase 2b results.
Multifaceted Declines in Everyday Decision-Making in Older Adults: A Think-Aloud Study
Older adults exhibit measurable declines in everyday decision-making driven by sensory and cognitive changes, with environmental design and support structures demonstrating capacity to mitigate these effects. This directly impacts functional independence and quality of life across the lifespan.
Activating and Strengthening Connection to Future Selves Boosts Retirement Preparation Among Middle-Aged Working Adults Over a 6-Month Period
An intervention connecting middle-aged adults to visualizations of their aged future selves increased retirement planning behaviors over six months. This addresses a critical gap between knowledge and action—most people understand retirement requires planning, yet fail to execute sustained preparation.
Galectin‐9high Neutrophils Exacerbate Radiation‐Induced Frailty
Local radiation injury triggers a cascade in which damaged skin cells release eccDNA, activating immune signaling in the spleen that produces hyperactive neutrophils expressing high levels of galectin-9. These neutrophils infiltrate multiple organs, disrupt bone marrow function, and drive sustained immune dysregulation that accelerates frailty—a finding that identifies a specific mechanistic pathway underlying radiation-induced aging and functional decline.
What animals can teach us about reversing age-related disease
Researchers studying animals that recover from extreme stress—hibernating ground squirrels and aging dogs—are identifying reversible mechanisms of age-related disease that human datasets alone may never reveal. This approach reframes aging as a problem with existing biological solutions rather than inevitable decline.
APOE4 Increases Neurons’ Excitability Before Symptoms Appear
APOE4 carriers exhibit elevated neuronal excitability in specific hippocampal regions during youth, before cognitive symptoms manifest, with early excitability patterns predictive of later cognitive decline. This mechanism resembles accelerated aging and offers a window for intervention before irreversible neurodegeneration.
Cymbiotika partners with Gary Brecka for precision wellness
Cymbiotika has partnered with human biologist Gary Brecka to integrate liposomal nutrient delivery technology into Brecka's protocol-driven wellness framework. The collaboration aims to improve nutrient bioavailability through formulations targeting energy, recovery, and metabolic health, with Cymbiotika claiming up to three times greater absorption in select products.
Beacon Biosignals upsizes Series B to more than $97 million
Beacon Biosignals raised $97 million in Series B extension funding to advance at-home EEG technology and AI-driven neural analytics for diagnostic and clinical applications. The capital supports commercialization of FDA-cleared wearable technology that captures real-world brain activity data for precision medicine.
Generare bags $21.6m for nature-derived drug leads
Generare raised $21.6 million to build a proprietary library of previously undiscovered small molecules derived from microbial genomes, addressing a fundamental constraint in drug discovery: the field's reliance on recycled chemical data rather than genuinely novel molecular diversity. Access to unexplored biological chemistry may prove more rate-limiting than algorithmic advancement in identifying future therapeutics.
New CAR-T approach may extend osteosarcoma survival
Preclinical research demonstrates that OSM CAR-T, an engineered immune-cell therapy targeting oncostatin M receptors, shows anti-tumor activity against osteosarcoma in cell and animal models, including metastatic disease. This represents the first meaningful advancement in a disease whose standard treatment has remained unchanged for four decades.
Allergan Aesthetics finds its next growth engine in GLP-1s
GLP-1 weight-loss medications are creating a new patient population in aesthetic medicine, with 52% of GLP-1-treated patients expressing concerns about facial appearance changes and 32% being new to aesthetic practices. This represents market expansion rather than simple demand shifting, driven by patients seeking natural-looking, lower-commitment interventions to address facial volume loss during weight loss.
Exposure, Reporting, and Distress Following Sexual Harassment in Geriatric Care
Sexual harassment in geriatric care settings correlates with psychological distress and low reporting rates among staff and patients. Understanding exposure patterns and barriers to disclosure is critical for identifying how institutional stress undermines health outcomes in aging populations and healthcare workers alike.
Double‐Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration
A combination of NMN and apigenin preserves NAD+ levels, activating SIRT3 to suppress cellular senescence and promote differentiation of muscle, bone, and cartilage precursor cells. The regimen also modulates the gut microbiota to increase production of phytosphingosine, an anti-aging metabolite, resulting in improved musculoskeletal function and exercise capacity in aged animals.
Caregiver Burden and Quality of Life Among Caregivers of Beneficiaries in a Long-Term Care Insurance Program
Family caregivers receiving long-term care insurance benefits experience measurable burden and quality-of-life decline despite financial support. The research identifies specific stressors that persist independent of insurance coverage, indicating that economic intervention alone does not resolve the physiological and psychological toll of sustained caregiving.
Strengthening Support for Immigrant Direct Care Workers: Recommendations from Experienced Direct Care Workers for People Living with Dementia
Immigrant direct care workers comprise 27% of the U.S. direct care workforce but face documented barriers in dementia care settings. The study identifies systemic support gaps and worker-generated recommendations for improving retention and quality of care delivery in this population.
Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes
Aging in rats produces sex-dependent changes in emotional regulation, cognitive function, and brain immune cell populations, with females showing greater cognitive decline and males exhibiting more pronounced emotional dysregulation. These findings suggest that neuroinflammation and immune cell dynamics contribute to cognitive and emotional aging, with implications for understanding sex-specific vulnerabilities in human neurodegenerative conditions.
A Target for Ameliorating Post-Operative Delirium
Post-operative delirium accelerates cognitive decline in older adults, particularly those with existing mild cognitive impairment, through microglial activation and metabolic reprogramming in the hippocampus. Suppressing RUVBL2 expression in animal models restores cognitive function, reduced inflammation, and normalized energy metabolism, positioning this protein as a potential therapeutic target.
WELL Health partners with AliveCor for cardiac monitoring in Canada
WELL Health has integrated Canadian cardiologists into AliveCor's Kardia platform to provide physician-reviewed ECG interpretation within 24 hours, addressing documented gaps in cardiology access where wait times have risen 53% nationally. This partnership combines AI-powered arrhythmia detection with human clinical validation to expand remote cardiac monitoring capacity.
Serum‐Derived Extracellular Vesicles as Biological Indicator of Mobility Resilience in Older Adults
Serum extracellular vesicles carry distinct molecular signatures—small noncoding RNAs and mitochondrial proteins—that differentiate older adults with preserved mobility from those with age-related gait decline. These circulating vesicles appear to mediate brain-muscle communication and may serve as noninvasive biomarkers for identifying individuals at risk of functional decline.
Catalyst Precision Health debuts at-home men’s longevity care
Catalyst Precision Health launches an integrated model combining in-home testing, physician house calls, and continuous personalized care for men's longevity, addressing fragmentation in the current market where health data remains scattered across disconnected providers and platforms.
Agentis, Ultrahuman tie wearables to longevity care
Agentis Longevity and Ultrahuman have partnered to integrate continuous biosensor data with clinical longevity tracking through the Longevity Quotient (LQ) score, creating real-time health monitoring between clinic visits. The collaboration addresses a critical gap in preventive care: translating isolated health data into actionable patterns that reflect actual lifestyle and physiological changes.
Noom buys pharmacy to push into healthy aging
Noom acquired Tailor Made Compounding, a licensed 503A pharmacy operating across 46 states, to integrate prescription-grade therapies with behavioral coaching and establish a comprehensive preventive care platform. This move positions the company to expand beyond weight management into broader healthy aging interventions including peptide therapies and metabolic support.
Respiratory Symptom Burden and Quality of Life Among Older Adults Amidst Climate Change: A Descriptive Rapid Survey in Indonesia
Climate change-driven environmental conditions increase respiratory symptom burden in older adults, with direct implications for quality of life and functional capacity. This finding underscores how environmental stressors compromise respiratory function and downstream health trajectories during aging.
#386 – Aging clocks—what they measure, how they work, and their clinical and real-world relevance
Aging clocks are biomarkers that quantify biological age independent of chronological time, offering a measurable framework to evaluate whether interventions actually slow aging. Their clinical utility depends on validating what they measure, understanding their mechanisms, and establishing whether changes in these markers correlate with meaningful health outcomes.
Senescent Factors Suppress Innate Antiviral Immunity in Aged Mice via Two Distinct Mechanisms
Senescent cells accumulate with age and suppress antiviral immunity through four secreted factors—GDF15, IGF1, IL1α, and IL6—via two distinct signaling pathways. Blocking these factors restores innate antiviral defense in aged mice, offering a mechanistic target to improve immune resilience against infection in older adults.
Extracellular vesicles derived from senescent hepatocytes drive pan-cancer metastasis in aging
Senescent hepatocytes in aging release extracellular vesicles containing microRNAs that enhance metastatic potential across multiple cancer types in aged organisms. This mechanism directly links hepatic aging to systemic cancer progression, identifying a previously uncharacterized pathway connecting liver dysfunction to increased metastatic risk in older adults.
HCCaging: a liver physiological aging-related biomarker for hepatocellular carcinoma diagnosis based on transcriptome data
Researchers identified HCCaging, a transcriptome-based biomarker that reflects liver aging patterns and improves hepatocellular carcinoma diagnosis. This tool bridges the gap between cellular aging processes and cancer risk stratification, offering earlier detection potential before advanced disease.
Biomarkers of oxidative damage as a tool to investigate frailty syndrome in older women
Oxidative damage biomarkers correlate with frailty in older women, providing measurable indicators of cellular stress that precede functional decline. Identifying these markers enables earlier intervention before frailty manifests clinically.
Plasma Proteomic Profiling of Young and Older Adults Identifies Candidate Biomarkers of Biological Aging at the Intersection of Age and Disease
Proteomic analysis identified 311 plasma proteins whose expression patterns correlate with both chronological age and disease burden in older adults, representing candidate biomarkers of biological aging. These proteins suggest shared regulatory pathways between aging and chronic disease progression and may enable risk stratification and intervention monitoring.
The Effectiveness of an Audiovisual and Game-Based Dementia Educational Program on Healthcare Students’ Attitude: A Pre-post Comparative Study
An audiovisual game-based educational program improved healthcare students' attitudes toward dementia, demonstrating that interactive learning methods can shift perception and potentially influence future clinical care quality. This has indirect relevance to longevity contexts where provider attitudes shape patient outcomes and engagement with cognitive health management.
Elevated trimethylamine levels characterize impaired muscle mass response to leucine-enriched protein supplementation in older adults at risk of sarcopenia
Elevated trimethylamine—a gut-derived metabolite—predicts which older adults will fail to gain muscle mass from leucine-enriched protein supplementation. This biomarker distinction reveals that sarcopenia interventions require individual metabolic assessment, not one-size-fits-all protocols.
scAgeClock: a single-cell transcriptome-based human aging clock model using gated multi-head attention neural networks
Researchers developed scAgeClock, a machine learning model that measures aging at the single-cell level by analyzing gene expression patterns. This cellular-resolution aging clock offers a novel method to detect age-related changes before systemic symptoms emerge, with potential applications in monitoring intervention efficacy and identifying individuals at accelerated aging risk.
Extracellular matrix: new insights into its role in female reproductive aging and potential therapeutic strategies
The extracellular matrix—the structural scaffold surrounding reproductive tissues—undergoes progressive degradation during female reproductive aging, compromising ovarian function and fertility. Targeting matrix preservation and remodeling represents a mechanistic approach to extending reproductive lifespan and potentially supporting broader aging-related outcomes.
Insilico and Eli Lilly Announce a Major Collaboration
Eli Lilly's $2.75 billion collaboration with Insilico Medicine represents a shift from software licensing to pipeline asset acquisition, validating AI-driven drug discovery as a viable approach to therapeutic development. This partnership signals pharmaceutical industry confidence in computational approaches to identifying and developing novel compounds, with potential applications across multiple disease areas including aging-related conditions.
Featured Cover
Plasma proteomic analysis of Swiss centenarians identifies a distinct protein signature associated with preserved youthfulness and longevity. This proteomic fingerprint offers a measurable biomarker set for aging trajectories and potential intervention targets.
RUVBL2 Regulates Microglia Metabolic Reprogramming to Mediate Stress Granules Aggregation Exacerbating Postoperative Delirium in Aged Mild Cognitive Impairment Rats
RUVBL2 protein drives metabolic reprogramming in immune cells of the brain, shifting them toward glucose metabolism and triggering protein aggregation that accelerates cognitive decline after surgery in aging. Reducing RUVBL2 expression reverses this metabolic shift, reduces neuroinflammation, and preserves cognitive function in aged animals with mild cognitive impairment.
Curve Bio strengthens clinical push with CMO hire
Curve Biosciences appointed hepatologist Dr. Amit Singal as Chief Medical Officer to advance clinical translation of its circulating DNA diagnostic platform for early organ dysfunction detection. The move signals a strategic shift from technology development toward embedding blood-based diagnostics into existing clinical workflows, beginning with liver disease where earlier intervention can measurably alter patient outcomes.
Occupational health meets longevity
Occupational health is shifting from compliance and risk mitigation toward prevention and long-term healthspan management, with employers increasingly positioned as agents of intervention during midlife—a critical window for altering disease trajectories. This convergence creates both opportunity and tension: while employers can scale prevention through their workforce, questions of privacy, data ownership, and equity remain unresolved.
Updated cardiovascular guidelines—statin use in patients as young as 30
Updated cardiovascular guidelines now recommend statin consideration for primary prevention in patients as young as 30 based on atherosclerotic cardiovascular disease risk assessment, shifting the threshold earlier than traditional practice. This reflects growing evidence that atherosclerotic burden begins decades before clinical events, making earlier intervention a potential strategy to reduce lifetime cardiovascular risk.
Biological clocks age within a day without you aging!
Biological age clocks derived from DNA methylation patterns show significant day-to-day fluctuations within individuals, independent of actual chronological aging. This instability raises critical questions about their reliability for clinical application and longevity intervention assessment.
Prediabetes may need a tailored treatment rethink
Among younger adults with prediabetes, risk of progression to Type 2 diabetes varies dramatically—from 7.5% overall to 24.8% for those with elevated fasting glucose and obesity-related criteria. Current treatment approaches fail to distinguish between slow progressors and rapid progressors, missing opportunities for early intervention in high-risk individuals.
Superpower partners with Grail to add Galleri cancer screening
Superpower has integrated Galleri, a multi-cancer early detection blood test, into its preventative health platform. Data from PATHFINDER 2 showed that adding Galleri to standard screening increased cancer detection more than seven-fold, with over half of detected cancers identified at stage I or II.
Well Health partners with AliveCor for cardiologist review
Well Health and AliveCor have integrated Canadian cardiologist review into the Kardia mobile ECG platform, enabling users to obtain physician-evaluated cardiac assessments within 24 hours. This addresses extended specialist wait times while maintaining clinical oversight of AI-detected arrhythmias and cardiac conditions.
Designs for Health launches NeuroCalm Peptide for gut-brain support
Designs for Health introduced NeuroCalm Peptide, combining a milk-derived peptide (Lactium) with a heat-treated Lactobacillus strain to modulate the gut-brain axis. Clinical evidence suggests the formulation may reduce perceived stress and salivary cortisol while supporting sleep quality and emotional resilience through microbiome and nervous system pathways.
Annovis wins U.S. patent for Buntanetap in brain infection injuries
Annovis secured a U.S. patent for buntanetap covering prevention and treatment of neurological injury from brain infections by reducing neurotoxic protein aggregation. The patent extends through 2044 and encompasses a broad range of infectious agents implicated in neurological damage.
Psilocybin and human longevity
Psilocybin demonstrates measurable effects on lifespan and healthspan markers in preclinical models, operating through neuroplasticity pathways and stress-response modulation. The compound's capacity to alter consciousness-linked neural signaling raises questions about its role in longevity pathways previously associated with psychological resilience and systemic stress tolerance.
Imaging-derived biological age across multiple organs links to mortality and aging-related health outcomes
Imaging-derived biological age—a measure of structural aging across multiple organs—independently predicts mortality and age-related disease risk beyond chronological age. This multi-organ assessment reveals that heterogeneous aging patterns across tissues provide clinically actionable information for longevity planning and intervention timing.
The case for space as a model of accelerated aging
Spaceflight stressors including microgravity and radiation accelerate biological aging pathways in astronauts, providing a compressed model for studying age-related disease mechanisms. This natural experiment offers direct evidence of how extreme environmental conditions trigger aging processes that occur more gradually in terrestrial populations.
Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer’s disease pathogenesis
Young mice carrying the APOE4 gene variant show excessive electrical activity in the hippocampus before cognitive decline becomes apparent, a pattern driven by neuronal APOE4 expression itself. This early hyperexcitability represents a tractable target for intervention, as it can be reversed through modulation of the Nell2 pathway.
How an Enzyme’s Depletion Makes Fat Worse
Pck1 enzyme depletion in adipose tissue accelerates cellular senescence and metabolic dysfunction, linking metabolic enzyme loss to accelerated aging in fat cells. This identifies a specific enzymatic mechanism by which declining metabolic capacity in aging tissue drives the accumulation of senescent cells and their inflammatory consequences.
[Articles] Risk factors for early-onset and late-onset dementia: a prospective cohort study
Modifiable risk factors drive both early-onset and late-onset dementia, with distinct profiles emerging between the two presentations. Identifying these factors creates measurable intervention points for primary prevention before cognitive decline becomes apparent.
The ‘rising tide’ of mitochondrial therapies in longevity
Mitochondrial dysfunction is increasingly recognized as a central mechanism underlying age-related disease, not merely a feature of rare genetic conditions. The FDA approval of elamipretide (Forzinity) for Barth syndrome represents the first regulatory validation of mitochondria-targeted therapeutics, positioning this class of drugs as potential interventions for common age-related conditions including neurodegeneration and cardiac disease.
SpectraCell packages longevity, early disease detection in one kit
SpectraCell's Baseline Nexus bundles four diagnostic tests—micronutrient status, lipoprotein particle profiling, telomere length, and MTHFR genotyping—into a single assessment designed to identify subclinical dysfunction before it progresses to clinical disease. The package reframes preventive diagnostics by measuring intracellular nutrient utilization and biological aging markers alongside conventional cardiovascular risk factors, enabling earlier intervention at the stage where metabolic and inflammatory processes are still modifiable.
Rhythm posts first FDA approval for acquired hypothalamic obesity
IMCIVREE (setmelanotide) received FDA approval as the first therapy for acquired hypothalamic obesity, a rare condition where brain injury disrupts hunger and energy regulation. The Phase 3 TRANSCEND trial demonstrated an 18.4% BMI reduction versus placebo at 52 weeks, addressing a previously untreated disorder that causes relentless weight gain despite behavioral intervention.
Annovis publishes historical review of Buntanetap
Annovis published a historical review of Buntanetap, tracing its development from 19th-century origins through current Phase 3 clinical trials for Alzheimer's and Parkinson's disease. The compound uses an RNA-targeting mechanism to inhibit translation of neurotoxic proteins implicated in neurodegeneration.
Humanaut to open Dallas clinic, launches founding membership presale
Humanaut is opening a Dallas clinic in May 2026 and offering founding memberships at a locked rate of $2,700 annually, which includes comprehensive biomarker assessments, body composition tracking, cardiovascular imaging, and access to therapeutic modalities such as hyperbaric oxygen and cryotherapy. This represents an expansion of a clinic-based longevity model that integrates baseline measurement with targeted interventions.
Agentis, Ultrahuman tie wearables to Longevity Quotient
Agentis Longevity and Ultrahuman have integrated continuous glucose monitoring and wearable biomarker data into a clinical scoring system (Longevity Quotient) designed to bridge the gap between real-time metabolic data and actionable preventive care. The partnership addresses low engagement in preventive health practices by making personalized, data-driven interventions accessible at scale.
I-Lumen receives FDA IDE to start U.S. i-SIGHT2 enrollment
I-Lumen Scientific received FDA approval to expand enrollment of i-SIGHT2, a clinical trial evaluating non-invasive bioelectric stimulation for intermediate to advanced dry age-related macular degeneration. The therapy aims to restore retinal function through microcurrent stimulation of the retinal pigment epithelium, with U.S. enrollment beginning in late April 2026.
In Vitro Modeling of Age‐Associated Lipid Mediator's Impact on Vascular Biology Following Platelet Concentrate Transfusion
Lipid mediators in platelet transfusions—particularly lysophosphatidic acid, lysophosphatidylcholine, and sphingosine-1-phosphate—decline with donor age and correlate with adverse transfusion reactions through altered platelet and endothelial cell activation. This finding suggests that donor age-related changes in lipid signaling directly influence transfusion safety and vascular biology.
Becoming Well-Fed and Sedentary Accelerates Penguin Aging
King penguins transitioning from wild to zoo environments—characterized by reduced physical activity and continuous food availability—show accelerated epigenetic aging of 2.5 to 6.5 years compared to wild counterparts, despite longer overall survival due to absence of predation and medical care. This model demonstrates that metabolic and behavioral patterns associated with sedentary, nutrient-abundant lifestyles drive molecular aging markers independently of lifespan.
Kailera plots IPO to fuel obesity pipeline
Kailera Therapeutics, backed by $1.6 billion in funding, is pursuing an IPO to advance its GLP-1-based obesity drug pipeline, with ribupatide showing 18-23% weight loss in trials. The company's capital requirements reflect how quickly the competitive landscape has shifted—efficacy alone no longer differentiates; payers now demand real-world outcomes data and cost justification.
20/20 BioLabs expands longevity test with kidney risk tech
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm to expand its longevity testing platform beyond inflammation markers into earlier risk detection. The addition addresses a substantial gap: over 35 million Americans have chronic kidney disease, yet most remain unaware until significant progression occurs, making early identification clinically actionable for preventing age-related decline.
Enlivex clears pivotal FDA hurdle in knee osteoarthritis
Enlivex received FDA clearance to advance Allocetra, an immunotherapy delivered directly into the knee joint, into Phase 2b trials for moderate-to-severe age-related knee osteoarthritis. This represents a critical transition from early-stage evidence to rigorous testing in a therapy designed to modify disease progression rather than manage symptoms alone—a gap that currently defines treatment of one of aging's most prevalent mobility constraints.
Rejuvenation Roundup March 2026
This roundup summarizes March 2026 longevity research across multiple domains: mechanisms linking energy production to neurodegeneration, exercise's effect on brain aging, immunosenescence factors, organ-level aging processes, and the interconnection between microbiome composition, psychological state, and systemic aging. The findings collectively advance understanding of how interventions—from resistance training to nutritional composition to social environment—modulate the rate of age-related decline.
Burnout Among Direct Care Workers in Chinese Long-term Care Facilities: A Multilevel Analysis Integrating the Stress Process and Job Demands–Resources Models
Burnout among direct care workers in Chinese long-term care facilities correlates with job demands, resource availability, and individual stress responses. Understanding these multilevel factors is critical for sustaining the quality of care delivered to aging populations and protecting workforce stability in geriatric settings.
Anavex updates regulatory strategy for blarcamesine
Anavex Life Sciences adjusted its regulatory approach for blarcamesine, withdrawing its EU marketing authorization application for Alzheimer's disease while pursuing alternative pathways with European and U.S. authorities. The compound is in advanced clinical development across multiple neurodegenerative conditions, including early Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome.
Insilico Medicine, Lilly partner on AI-driven drug discovery deal
Insilico Medicine and Eli Lilly have established a drug discovery partnership leveraging AI to accelerate identification and development of oral therapeutics across multiple disease areas. This collaboration represents a shift in pharmaceutical R&D methodology toward computational drug discovery, with potential implications for reducing development timelines and costs in longevity-related therapeutic areas.
New data show TrenibotE safety in repeat treatments
TrenibotE, an investigational neurotoxin, demonstrated consistent safety across repeat treatments with rapid onset at eight hours and duration of two to three weeks, with no neutralizing antibody development. Concurrent survey data indicate that over half of GLP-1–treated patients express concerns about facial appearance, with cost and fear of unnatural results as primary barriers to aesthetic intervention.
Stem cell therapy might improve aging frailty
Stem cell therapy demonstrates potential to address frailty in aging by restoring cellular repair capacity and tissue regeneration. This approach targets a fundamental mechanism of aging decline rather than managing symptoms.
Individual differences reveal distinct age-related reorganizations in spatial channels for luminance and texture processing
Aging produces distinct, individual-level reorganization in how the visual cortex processes luminance and texture information, with spatial channel organization varying significantly across people. These findings suggest that visual processing changes in aging are not uniform but reflect personalized neural reorganization patterns that could inform how we understand and potentially intervene in age-related cognitive decline.